KR102637453B1 - Cosmetic materials for improving acnegenic skin, Manufacturing method thereof and Cosmetics containing the same - Google Patents
Cosmetic materials for improving acnegenic skin, Manufacturing method thereof and Cosmetics containing the same Download PDFInfo
- Publication number
- KR102637453B1 KR102637453B1 KR1020210157592A KR20210157592A KR102637453B1 KR 102637453 B1 KR102637453 B1 KR 102637453B1 KR 1020210157592 A KR1020210157592 A KR 1020210157592A KR 20210157592 A KR20210157592 A KR 20210157592A KR 102637453 B1 KR102637453 B1 KR 102637453B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- herbal medicine
- fermented
- extract
- cosmetic
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 114
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 26
- 239000000463 material Substances 0.000 title description 4
- 230000002333 acnegenic effect Effects 0.000 title 1
- 241000411851 herbal medicine Species 0.000 claims abstract description 108
- 239000000284 extract Substances 0.000 claims abstract description 88
- 206010000496 acne Diseases 0.000 claims abstract description 44
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 34
- 238000000855 fermentation Methods 0.000 claims description 81
- 230000004151 fermentation Effects 0.000 claims description 81
- 239000000047 product Substances 0.000 claims description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- 239000003795 chemical substances by application Substances 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 34
- 238000002156 mixing Methods 0.000 claims description 27
- 239000002131 composite material Substances 0.000 claims description 25
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 23
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 18
- 235000009008 Eriobotrya japonica Nutrition 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 14
- 240000008397 Ganoderma lucidum Species 0.000 claims description 14
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 14
- 240000005979 Hordeum vulgare Species 0.000 claims description 14
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 14
- 240000003553 Leptospermum scoparium Species 0.000 claims description 14
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 14
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- 235000003826 Artemisia Nutrition 0.000 claims description 10
- 244000030166 artemisia Species 0.000 claims description 10
- 235000009052 artemisia Nutrition 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 8
- 238000005292 vacuum distillation Methods 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 244000061508 Eriobotrya japonica Species 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 238000010025 steaming Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 244000028344 Primula vulgaris Species 0.000 claims description 4
- 235000016311 Primula vulgaris Nutrition 0.000 claims description 4
- 241000219793 Trifolium Species 0.000 claims description 4
- 241001633574 Adenophora stricta Species 0.000 claims description 3
- 235000001405 Artemisia annua Nutrition 0.000 claims description 3
- 240000000011 Artemisia annua Species 0.000 claims description 3
- 241000392544 Dendropanax morbifer Species 0.000 claims description 3
- 241000534017 Saururus chinensis Species 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 210000004761 scalp Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 37
- 230000006872 improvement Effects 0.000 abstract description 20
- 239000004615 ingredient Substances 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 description 63
- 238000002360 preparation method Methods 0.000 description 51
- 230000000052 comparative effect Effects 0.000 description 50
- 210000002374 sebum Anatomy 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 13
- 102000003425 Tyrosinase Human genes 0.000 description 13
- 108060008724 Tyrosinase Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 241001092070 Eriobotrya Species 0.000 description 12
- 230000037303 wrinkles Effects 0.000 description 12
- 238000009472 formulation Methods 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 235000021422 persimmon vinegar Nutrition 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 7
- 230000002292 Radical scavenging effect Effects 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- -1 ABTS cation Chemical class 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000004909 Moisturizer Substances 0.000 description 6
- 102000016387 Pancreatic elastase Human genes 0.000 description 6
- 108010067372 Pancreatic elastase Proteins 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000001333 moisturizer Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 6
- 230000008591 skin barrier function Effects 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000208340 Araliaceae Species 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002849 elastaseinhibitory effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 230000002087 whitening effect Effects 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 229940059958 centella asiatica extract Drugs 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000749 insecticidal effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 230000005808 skin problem Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 238000004506 ultrasonic cleaning Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 244000148064 Enicostema verticillatum Species 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010027626 Milia Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 241000245032 Trillium Species 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940067866 dandelion extract Drugs 0.000 description 2
- 235000020691 dandelion extract Nutrition 0.000 description 2
- 230000004665 defense response Effects 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000001027 hydrothermal synthesis Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 230000036555 skin type Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000020238 sunflower seed Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000001845 taraxacum officinale leaf extract Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241001128004 Demodex Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 206010027627 Miliaria Diseases 0.000 description 1
- 244000230712 Narcissus tazetta Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010056658 Pseudocyst Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000245665 Taraxacum Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Abstract
본 발명은 천연 한약재를 포함하는 화장료, 이의 제조방법 및 이를 이용한 화장품에 관한 것으로서, 좀 더 구체적으로 설명하면, 황칠나무 등 7종의 천연 한약재 추출물을 발효시킨 발효물을 이용한 천연 식물 성분 유래의 여드름 피부 개선 효과가 우수한 화장료, 이의 제조방법 및 이를 이용한 기능성 화장품에 관한 것이다.The present invention relates to cosmetics containing natural herbal medicines, methods for producing the same, and cosmetics using the same. To be more specific, the present invention relates to acne treatment derived from natural plant ingredients using fermented extracts of seven types of natural herbal medicines such as Hwangchil tree. It relates to cosmetics with excellent skin improvement effects, their manufacturing methods, and functional cosmetics using them.
Description
본 발명은 천연 한약재를 이용한 천연 식물 성분 유래의 여드름 개선 효과가 우수한 화장료, 이의 제조방법 및 이를 이용한 여드름 개선 효과가 있는 화장품에 관한 것이다.The present invention relates to a cosmetic with an excellent acne-improving effect derived from natural plant ingredients using natural herbal medicine, a method for producing the same, and a cosmetic with an acne-improving effect using the same.
여드름(Acne)은 주로 얼굴, 목, 가슴, 등, 어깨 부위에 면포, 구진, 고름물집, 결절, 거짓낭 등이 발생하는 염증성 피부 질환이다. 여드름은 대개 10대 초반에 발생하나, 20대 전후에 증상이 심해질 수도 있으며, 30대와 40대 성인에게도 발생할 수 있다. 치료를 하지 않아도 보통 수년 후에 없어지지만 치료하지 않을 경우 영구적인 흉터를 남길 수 있어 미용적인 문제가 되며, 생명을 위협하는 병은 아니지만 환자에게 심리적인 부담을 준다.Acne is an inflammatory skin disease that causes comedones, papules, pus blisters, nodules, and pseudocysts to occur mainly on the face, neck, chest, back, and shoulders. Acne usually occurs in the early teens, but symptoms can worsen around the 20s and can also occur in adults in their 30s and 40s. Even without treatment, it usually disappears after several years, but if left untreated, it can leave permanent scars, which becomes a cosmetic problem. Although it is not a life-threatening disease, it places a psychological burden on the patient.
여드름의 정확한 원인은 아직 확실히 밝혀져 있지 않지만, 여러 원인이 복합적으로 작용하는 것으로 알려져 있다. 사춘기 동안 증가된 남성호르몬은 피부의 피지선(피부 기름샘)을 커지게 하고, 이들 피지선에서 피지라 불리는 기름 물질이 생성되는데, 이러한 피지 분비가 많아지면 피지가 모낭의 내벽을 자극하여 내벽세포가 더 빨리 탈락하도록 만들고, 이 탈락한 세포들은 엉겨서 모낭의 구멍을 막아 여드름의 기본 병변인 면포(comedone, 모낭 속에 고여 딱딱해진 피지)가 된다. 또한, 모낭 내에 상주하는 균이 분비하는 지방분해효소가 피지 중의 중성지방을 분해하여 유리 지방산을 형성하는데, 형성된 유리 지방산은 다시 모낭을 자극하여 모낭 벽을 터트려, 피지, 세균, 탈락된 세포들이 피부로 방출되어 홍반, 부종, 고름을 생기게 한다.The exact cause of acne is not yet clear, but it is known that several causes work together. Male hormones increased during puberty cause the sebaceous glands of the skin (skin oil glands) to enlarge, and these sebaceous glands produce an oily substance called sebum. When this sebum secretion increases, the sebum stimulates the inner wall of the hair follicle, causing the inner wall cells to grow more. It causes them to fall out quickly, and these shed cells clump together and block the pores of the hair follicles, forming comedones (sebum that accumulates and hardens in the hair follicles), which is the basic lesion of acne. In addition, lipolytic enzymes secreted by bacteria residing in hair follicles break down neutral fats in sebum to form free fatty acids. The formed free fatty acids stimulate the hair follicles again to burst the hair follicle walls, allowing sebum, bacteria, and shed cells to enter the skin. It is released and causes erythema, edema, and pus.
여드름을 치료하기 위해서는 꾸준한 관리가 필요하며, 오래 복용하거나 접하더라도 부작용이 적고 안전하며 여드름 치료에 효과적인 천연물 소재가 필요하다. 이와 같이 천연 소재 유래의 다양한 여드름 개선 및/또는 예방 성분에 대한 많은 연구 및 제품이 개발되고 있으며, 피부 트러블 등의 부작용을 최소화시킬 수 있으면서 다양한 응용 제품에 적용할 수 있는 여드름 개선 효과가 있는 화장료에 대한 요구가 증대하고 있는 실정이다.In order to treat acne, consistent management is required, and natural ingredients are needed that are safe and have few side effects even if taken or used for a long time and are effective in treating acne. As such, many researches and products are being developed on various acne improvement and/or prevention ingredients derived from natural materials, and cosmetics with acne improvement effects that can be applied to various application products while minimizing side effects such as skin troubles are being developed. The demand for it is increasing.
본 발명은 피부 부작용을 방지 및 최소화시키면서 여드름 개선 효과가 있는 화장료를 개발하고자 노력한 결과, 최적의 조성 및 조성비를 가지는 여드름 개선 화장료 소재 및 이의 조성비를 알게 되어 본 발명을 완성하게 되었다. 즉, 본 발명은 여드름 개선 화장료, 이를 제조하는 방법 및 이를 이용한 화장품을 제공하는데 본 발명의 목적이 있다.As a result of the present invention's efforts to develop a cosmetic that has an acne-improving effect while preventing and minimizing skin side effects, the present invention was completed by discovering an acne-improving cosmetic material with an optimal composition and composition ratio and its composition ratio. In other words, the purpose of the present invention is to provide an acne-improving cosmetic, a method for manufacturing the same, and cosmetics using the same.
상술한 과제를 해결하기 위하여 본 발명의 여드름 개선 화장료는 복합 한약재 발효물의 증류 추출물; 및 복합 한약재 발효물;을 포함하며, 상기 복합 한약재는 황칠나무(Dendropanax Morbifera), 비파나무 잎(Eriobotrya Japonica Leaf), 당잔대 잎 및 뿌리(Adenophora Stricta Leaf & Root), 새싹보리(Hordeum Vulgare), 삼백초(Saururus Chinensis), 개똥쑥 씨(Artemisia Annua seed) 및 티트리 잎(Tea Tree Leaf)를 포함한다.In order to solve the above problems, the acne improving cosmetic of the present invention includes distilled extract of fermented complex herbal medicine; and a complex herbal medicine fermentation product; the complex herbal medicine includes Dendropanax Morbifera, Eriobotrya Japonica Leaf, Adenophora Stricta Leaf & Root, Hordeum Vulgare, Includes Saururus Chinensis, Artemisia Annua seed and Tea Tree Leaf.
또한, 본 발명의 다른 목적은 상기 여드름 개선 화장료를 제조하는 방법으로서, 황칠나무, 비파나무 잎, 당잔대 잎 및 뿌리, 새싹보리, 삼백초, 개똥쑥 씨 및 티트리 잎의 혼합물을 초음파 세척한 후, 건조하여 건조된 복합 한약재를 준비하는 1단계; 상기 복합 한약재를 사용하여, 복합 한약재 발효물의 증류 추출물 및 복합 한약재 발효물을 각각 제조하는 2단계; 및 상기 복합 한약재 발효물의 증류 추출물 및 복합 한약재 발효물을 혼합하여 혼합액을 제조하는 3단계;를 포함하는 공정을 수행하여 제조할 수 있다.In addition, another object of the present invention is a method of manufacturing the acne-improving cosmetic, after ultrasonically washing a mixture of Hwangchil tree, loquat tree leaves, Dangjangi leaves and roots, barley sprouts, Trillium chinensis, Artemisia seeds and tea tree leaves. , the first step of preparing the dried composite herbal medicine; Step 2 of producing a distilled extract and a fermented complex herbal medicine, respectively, using the complex herbal medicine; and step 3 of mixing the distilled extract of the complex herbal medicine fermentation product and the complex herbal medicine fermentation product to prepare a mixed solution.
또한, 본 발명의 목적은 상기 화장료를 이용한 여드름 개선 효과가 우수한 화장품을 제공하고자 한다.In addition, the purpose of the present invention is to provide cosmetics with excellent acne improvement effects using the above cosmetics.
본 발명의 화장료는 피부 진정, 보습 효과가 우수하면서도, 피부 트러블이 없을 뿐만 아니라, 피부미백, 주름개선 및 여드름 개선 효과가 우수한 다양한 제형의 피부용 화장품, 샴푸, 린스 등의 두피 및 헤어용 화장품 등으로 화장료로 사용할 수 있다.The cosmetic of the present invention has excellent skin soothing and moisturizing effects, does not cause skin troubles, and is used as skin cosmetics in various formulations with excellent skin whitening, wrinkle improvement, and acne improvement effects, and scalp and hair cosmetics such as shampoo and conditioner. It can be used as a cosmetic.
도 1a 내지 도 1d는 실험예 1에서 실시한 사람 피부에 대한 안정성 평가 결과이다.
도 2 및 도 3은 화장품 내 살충 성분 함유 여부 측정 결과이다.Figures 1A to 1D show the results of the safety evaluation on human skin conducted in Experimental Example 1.
Figures 2 and 3 show the results of measuring whether cosmetics contain insecticidal ingredients.
이하, 본 발명의 여드름 개선 화장료를 제조하는 방법을 통해 더욱 구체적으로 설명한다.Hereinafter, a method for producing the acne-improving cosmetic of the present invention will be described in more detail.
본 발명의 여드름 개선 화장료는 황칠나무, 비파나무 잎, 당잔대 잎 및 뿌리, 새싹보리, 삼백초, 개똥쑥 씨 및 티트리 잎의 혼합물을 초음파 세척한 후, 건조하여 건조된 복합 한약재를 준비하는 1단계; 상기 복합 한약재를 사용하여, 복합 한약재 발효물의 증류 추출물 및 복합 한약재 발효물을 각각 제조하는 2단계; 및 상기 복합 한약재 발효물의 증류 추출물 및 복합 한약재 발효물을 혼합하여 혼합액을 제조하는 3단계;를 포함하는 공정을 수행하는 제조한다.The acne-improving cosmetic of the present invention is prepared by ultrasonically washing a mixture of Hwangchil tree, loquat tree leaves, Dangjangi leaves and roots, barley sprouts, trillium chinensis, artemisia seeds, and tea tree leaves, and then drying them to prepare the dried composite herbal medicine. step; Step 2 of producing a distilled extract and a fermented complex herbal medicine, respectively, using the complex herbal medicine; And step 3 of mixing the distilled extract of the complex herbal medicine fermentation product and the complex herbal medicine fermentation product to prepare a mixed solution.
1단계의 상기 혼합물은 비파나무 잎(Eriobotrya Japonica Leaf) 10 ~ 20 중량%, 당잔대 잎 및 뿌리(Adenophora Stricta Leaf & Root) 10 ~ 20 중량%, 새싹보리(Hordeum Vulgare) 10 ~ 20 중량%, 삼백초(Saururus Chinensis) 5 ~ 15 중량%, 개똥쑥 씨(Artemisia Annua seed) 5 ~ 15 중량% 및 티트리 잎(Tea Tree Leaf) 3 ~ 7 중량% 및 나머지 잔량의 황칠나무(Dendropanax Morbifera)를 포함할 수 있으며, 바람직하게는 비파나무 잎 12 ~ 18 중량%, 당잔대 잎 및 뿌리 14 ~ 20 중량%, 새싹보리 12 ~ 18 중량%, 삼백초 5 ~ 12 중량%, 개똥쑥 씨 8 ~ 14 중량%, 티트리 잎 3.5 ~ 7.0 중량% 및 나머지 잔량의 황칠나무를 포함할 수 있고, 더욱 바람직하게는 비파나무 잎 12 ~ 16 중량%, 당잔대 잎 및 뿌리 14 ~ 19 중량%, 새싹보리 13 ~ 18 중량%, 삼백초 7 ~ 12 중량%, 개똥쑥 씨 8.5 ~ 12.5 중량%, 티트리 잎 4.0 ~ 6.5 중량% 및 나머지 잔량의 황칠나무를 포함할 수 있다.The mixture in step 1 includes 10 to 20% by weight of Eriobotrya Japonica Leaf, 10 to 20% by weight of Adenophora Stricta Leaf & Root, 10 to 20% by weight of Hordeum Vulgare, Contains 5 to 15% by weight of Saururus Chinensis, 5 to 15% by weight of Artemisia Annua seeds, 3 to 7% by weight of Tea Tree Leaf, and the remaining amount of Dendropanax Morbifera. It can be done, preferably 12 to 18% by weight of loquat leaves, 14 to 20% by weight of dandelion leaves and roots, 12 to 18% by weight of sprouted barley, 5 to 12% by weight of Trifolium primrose, and 8 to 14% by weight of mugwort seeds. , it may include 3.5 to 7.0% by weight of tea tree leaves and the remaining amount of Hwangchil tree, more preferably 12 to 16% by weight of loquat leaves, 14 to 19% by weight of Danjangi leaves and roots, and 13 to 18% by weight of sprouted barley. % by weight, it may include 7 to 12% by weight of Trifolium primrose, 8.5 to 12.5% by weight of mugwort seeds, 4.0 to 6.5% by weight of tea tree leaves, and the remaining amount of Hwangchil tree.
그리고, 상기 황칠나무는 황칠나무의 잎, 줄기 및 열매의 혼합물을 포함한다.And, the Hwangchil tree includes a mixture of leaves, stems and fruits of the Hwangchil tree.
상기 비파나무 잎에는 환부에 붙이면 비파의 차가운 성질로 인하여 땀띠와 같은 열을 완화하는 효과와 비타민C가 함유 되어 있어 피부미용에 좋다. 또한 칼륨과 각종 미네랄도 풍부하게 함유 되어 있어 피부를 맑게 하여 주고 피부 트러블이 발생하지 않도록 건강한 피부를 유지 시켜 주는 효과를 위해 사용하는 것으로서, 상기 혼합물 전체 중량 중 비파나무 잎이 10 중량% 미만이면 비파나무 잎의 효능이 없는 문제가 있을 수 있고, 20 중량%를 초과하여 사용하면 비파나무잎의 차가운 성질로 인해 피부에 자극이 가해질 수 있는 문제가 있을 수 있다.The loquat tree leaves have the effect of relieving heat such as heat rash due to the cold nature of the loquat when applied to the affected area, and contain vitamin C, which is good for skin care. In addition, it is rich in potassium and various minerals, so it is used for the effect of clearing the skin and maintaining healthy skin to prevent skin troubles. If loquat tree leaves are less than 10% by weight of the total weight of the mixture, loquat There may be a problem of the tree leaves not being effective, and if used in excess of 20% by weight, there may be a problem of skin irritation due to the cold nature of the loquat tree leaves.
그리고, 상기 당잔대 잎 및 뿌리는 염증으로 인한 조직 손상을 막아주고, 다양한 감염원에 대한 생체조직 방어 반응 하는 효과를 위해 사용하는 것으로서, 혼합물 전체 중량 중 당잔대 잎 및 뿌리의 함량이 10 중량% 미만이면 유효성분이 포함되지 않아 조직의 손상, 외부의 자극으로부터 방어 반응 손상 등 염증성 질환의 예방이나 치료 효능이 현저히 떨어지는 문제가 있을 수 있고, 20 중량%를 초과하여 사용하면 독성이 없어 해는 없지만 과도하게 사용하면 오히려 질환의 주요 병리 현상(과민성 알러지 질환, 만성 염증 질환)으로 진행 하는 문제가 있을 수 있다.In addition, the leaves and roots of the Danjangi are used to prevent tissue damage due to inflammation and to provide a defense response to biological tissue against various infectious agents, and the content of the leaves and roots of the Danjangi is less than 10% by weight of the total weight of the mixture. Since it does not contain active ingredients, there may be problems with the efficacy of preventing or treating inflammatory diseases, such as tissue damage and impaired defense responses from external stimuli, being significantly reduced. If used in excess of 20% by weight, there is no harm as it is not toxic, but excessive use may result. If used, there may be a problem of the disease progressing to major pathologies (hypersensitivity allergic disease, chronic inflammatory disease).
그리고, 상기 새싹보리는 피부 트러블 완화, 피지 조절하는 효과를 위해 사용하는 것으로서, 혼합물 전체 중량 중 새싹보리 함량이 10 중량% 미만이면 피부 트러블 완화 하는 문제가 있을 수 있고, 20 중량%를 초과하여 사용하면 열수 추출물 발효시 미생물에 의한 발효가 잘 되지 않는 문제가 있을 수 있다.In addition, the sprout barley is used for the effect of alleviating skin troubles and controlling sebum. If the sprout barley content is less than 10% by weight of the total weight of the mixture, there may be a problem in alleviating skin troubles, and it is used in excess of 20% by weight. If so, there may be a problem that the fermentation by microorganisms does not work well during the fermentation of the hot water extract.
또한, 혼합물 전체 중량 중 상기 삼백초 함량이 5 중량% 미만이면 화장료의 피부 트러블 완화 증대 효과가 떨어질 수 있고, 15 중량%를 초과하면 열수 추출물 발효시 미생물에 의한 발효가 잘 되지 않고, 피부 세포 독성 문제가 생길 수 있다.In addition, if the amount of ginseng in the total weight of the mixture is less than 5% by weight, the effect of cosmetics in alleviating skin troubles may be reduced, and if it exceeds 15% by weight, fermentation by microorganisms does not work well during the fermentation of the hot water extract, and skin cell toxicity problems may occur. may occur.
그리고, 개똥쑥 씨는 플라보노이드 성분을 다량 포함하여, 항산화작용을 함으로서 세포 손상을 막아 주며 피부의 소염 작용하는 효과를 위해 사용하는 것으로서, 전체 중량 중 상기 개똥쑥 씨 함량이 5 중량% 미만이면 그 사용량이 적어서 항산화 효과 및 피부 진균 억제 효과가 떨어질 수 있고, 15 중량%를 초과하면 찬 성질이 피부의 혈액순환을 방해하여 뾰루지, 염증성 여드름, 피부 질환으로 악화하는 문제가 있을 수 있다.In addition, artemisia seeds contain a large amount of flavonoids, which prevent cell damage by acting as an antioxidant and are used for anti-inflammatory effects on the skin. If the content of artemisia seeds is less than 5% by weight of the total weight, the amount used is If this amount is small, the antioxidant effect and skin fungus suppressing effect may be reduced, and if it exceeds 15% by weight, the cold nature may interfere with blood circulation in the skin, which may worsen problems such as rashes, inflammatory acne, and skin diseases.
또한, 상기 티트리 잎은 살균 효과 및 과다 분비되는 피지량을 조절 하는 효과를 위해 사용하는 것으로서, 혼합물 전체 중량 중 티트리잎 함량이 3 중량% 미만이면 모낭충에 의한 여드름에 효과가 미비 하는 문제가 있고, 7 중량%를 초과하여 사용하는 것은 비경제적이고, 오히려 피부 트러블을 유발하는 문제가 있을 수 있으므로 상기 범위 내로 사용하는 것이 좋다.In addition, the tea tree leaves are used for the sterilizing effect and the effect of controlling the amount of excessive sebum secretion. If the tea tree leaf content of the total weight of the mixture is less than 3% by weight, there is a problem that the effect is insufficient for acne caused by Demodex. , It is uneconomical to use more than 7% by weight, and it may actually cause skin problems, so it is better to use it within the above range.
그리고, 상기 황칠나무는 두릅나무과에 속하며 세계에서 오직 대한민국 서남해안과 제주도에서만 자생하는 상록 활엽 교목으로 본초 강목에서는 황칠나무가 번열제거, 화상치료에 효과가 있으며 무해 하다고 기록되어 있다. 또한 황칠나무는 인삼처럼 사포닌성분이 많이 함유되어 인삼나무라고도 불리어 지고 있다. 황칠나무는 뛰어난 항산화 작용으로 인해 피부 노화를 막아 주고 멜라닌 색소를 막아주어 피부 미백효과에 사용하는 것으로서, 혼합물 전체 중량 중 앞서 설명한 비파나무 잎, 당잔대 잎 및 뿌리, 새싹보리, 삼백초, 개똥쑥 씨 및 티트리 잎 외에 100 중량% 중 나머지 잔량의 중량%로 사용할 수 있다.In addition, the Hwangchil tree belongs to the Araliaceae family and is an evergreen broad-leaved tree that grows only on the southwestern coast of Korea and Jeju Island in the world. In the herb class, Hwangchil tree is recorded to be effective in removing heat and treating burns and is harmless. In addition, Hwangchil tree is also called ginseng tree because it contains a lot of saponin components like ginseng. Hwangchil tree is used for skin whitening effect by preventing skin aging and melanin pigmentation due to its excellent antioxidant activity. Among the total weight of the mixture, the leaves and roots of loquat tree, daffodils leaves and roots, barley sprouts, ginseng herb, and artemisia seeds as described above are included in the total weight of the mixture. In addition to tea tree leaves, it can be used as a weight percent of the remaining amount out of 100 weight percent.
본 발명의 제조방법에 있어서, 1단계의 상기 초음파 세척은 당업계에서 사용하는 일반적인 초음파 세척 기기를 사용하여 수행할 수 있으며, 특별히 한정하지 않으며, 초음파 세척을 통해 중금속, 잔류 농약 등을 완전하게 제거를 수행한다.In the manufacturing method of the present invention, the ultrasonic cleaning in step 1 can be performed using a general ultrasonic cleaning device used in the industry, and is not particularly limited, and heavy metals and residual pesticides, etc. are completely removed through ultrasonic cleaning. Perform.
다음으로, 2단계는 1단계의 복합 한약재를 이용하여 발효물 및 상기 발효물의 증류 추출물을 각각 제조하는 공정이다.Next, the second step is a process of producing a fermented product and a distilled extract of the fermented product using the complex herbal medicine of the first step.
[복합 한약재 발효물의 증류 추출물][Distilled extract of fermented complex herbal medicine]
우선, 복합 한약재 발효물의 증류 추출물(이하, ‘증류 추출물’로 칭한다)은 다음과 같은 공정을 수행하여 제조할 수 있다.First, the distilled extract of the fermented complex herbal medicine (hereinafter referred to as ‘distilled extract’) can be produced by performing the following process.
상기 복합 한약재 발효물의 증류 추출물은, 상기 복합 한약재를 찜처리하는 2-1단계; 상기 찜 처리한 복합 한약재 및 물을 혼합한 후, 열처리하는 2-2단계; 열처리물을 여과한 후 냉각 처리하여 열수 추출물을 수득하는 2-3단계; 열수 추출물에 막걸리 효모 및 영지버섯 균사체 또는 상황버섯 균사체를 포함하는 발효제를 혼합한 후, 발효시킨 후, 여과하여 발효물을 수득하는 2-4단계; 및 상기 발효물을 진공 증류 추출공정을 수행하여 증류 추출물을 수득한 후, 여과하여 여과물을 수득하는 2-4단계;를 포함하는 공정을 수행하여 제조할 수 있다.The distilled extract of the fermented composite herbal medicine is obtained through a step 2-1 of steaming the composite herbal medicine; Step 2-2 of mixing the steamed composite herbal medicine and water, followed by heat treatment; Steps 2-3 of filtering the heat-treated product and then cooling it to obtain a hot water extract; Steps 2-4 of mixing the hot water extract with a fermentation agent containing makgeolli yeast and reishi mushroom mycelium or Sanghwang mushroom mycelium, fermenting it, and then filtering to obtain a fermented product; and steps 2-4 of performing a vacuum distillation extraction process on the fermented product to obtain a distilled extract and then filtering the fermented product to obtain a filtrate.
증류 추출물 제조공정에 있어서, 2-1 단계의 찜처리는 80 ~ 90℃의 증기를 2 ~ 4시간 동안 복합 한약재에 가하여 수행할 수 있다. 이때, 찜처리는 복합 한약재의 뿌리, 줄기와 같이 단단한 한약재와 잎, 열매와 같인 연한 한약재를 나누어서 찜 처리를 수행할 수 있으며, 일례를 들면, 뿌리, 줄기와 같이 단단한 한약재는 85 ~ 90℃ 하에서 3 ~ 4시간 찜 처리를 수행하고, 잎, 열매와 같인 연한 한약재는 80 ~ 85℃ 하에서 2 ~ 3시간 정도 찜 처리를 수행한 후, 이들을 혼합하여 2-2단계의 열처리 공정을 수행할 수 있다.In the distillation extract manufacturing process, steaming in step 2-1 can be performed by applying steam at 80 to 90°C to the composite herbal medicine for 2 to 4 hours. At this time, steaming treatment can be performed by dividing hard herbal medicines such as roots and stems of complex herbal medicines and soft herbal medicines such as leaves and fruits. For example, hard herbal medicines such as roots and stems can be steamed under 85 ~ 90℃. Steaming is performed for 3 to 4 hours, and soft herbal medicines such as leaves and fruits are steamed at 80 to 85°C for 2 to 3 hours, and then mixed to perform a 2-2 heat treatment process. .
증류 추출물 제조공정에 있어서, 2-2 단계의 열처리는 상기 찜 처리한 복합 한약재 및 물을 1 : 2.5 ~ 5.0 중량비로, 바람직하게는 1 : 2.8 ~ 5.0 중량비로 혼합한 후, 이를 85 ~ 95℃ 하에서 10 ~ 14시간 동안, 바람직하게는 88 ~ 92℃ 하에서 12 ~ 14시간 동안 수행한다. 이때, 물의 혼합량이 2.5 중량비 미만이면 열수 추출물 량이 너무 적은 문제가 있을 수 있고, 5.0 중량비를 초과하면 열수 추출물 내 피부에 유익한 유효성분 농도가 너무 낮고, 추후 발효가 잘 되지 않을 수 있으므로 상기 범위 내로 물과 혼합하여 열처리를 수행하는 것이 좋다.In the distillation extract manufacturing process, the heat treatment in step 2-2 is performed by mixing the steamed composite herbal medicine and water at a weight ratio of 1:2.5 to 5.0, preferably 1:2.8 to 5.0, and then heating the mixture at 85 to 95°C. for 10 to 14 hours under low temperature, preferably at 88 to 92°C for 12 to 14 hours. At this time, if the mixing amount of water is less than 2.5 weight ratio, there may be a problem that the amount of hot water extract is too small, and if it exceeds 5.0 weight ratio, the concentration of active ingredients beneficial to the skin in the hot water extract is too low and fermentation may not proceed well in the future, so water must be kept within the above range. It is recommended to perform heat treatment by mixing with .
증류 추출물 제조공정에 있어서, 2-3 단계는 2-2 단계의 열처리를 수행하여 수득한 열처리물을 여과 및 냉각 처리하여 열수 추출물을 수득하는 공정이며, 이때 여과 방법은 일반적인 방법으로 수행할 수 있으며, 열수 추출물 내 이물질, 잔여물 등 고형물을 포함하지 않으면 된다.In the distillation extract manufacturing process, step 2-3 is a process of obtaining a hot water extract by filtering and cooling the heat-treated product obtained by performing the heat treatment in step 2-2. At this time, the filtration method can be performed by a general method. , it must not contain solid matter such as foreign substances or residues in the hot water extract.
증류 추출물 제조공정에 있어서, 2-4 단계는 2-3 단계에서 수득한 열수 추출물을 발효시킨 발효물을 수득하는 공정으로서, 상기 열수 추출물 100 중량부에 대하여, 발효제 2.0 ~ 5.0 중량부를, 바람직하게는 발효제 2.2 ~ 4.0 중량부를 혼합한 후, 32 ~ 40℃ 하에서, 바람직하게는 36 ~ 40℃ 하에서, 45 ~ 60시간 동안, 바람직하게는 46 ~ 52시간 동안 발효시킨 후, 여과하여 발효물을 수득하는 공정이다. 이때, 상기 발효제의 사용량이 2.0 중량부 미만이면 발효가 잘 진행되지 않는 문제가 있을 수 있고, 발효제 사용량이 5.0 중량부를 초과하더라도 발효 진행 속도가 더 빨라지지 않으며, 수득되는 발효물 양이 증가하지 않으며, 오히려 수득된 발효물을 이용한 화장료가 피부 트러블을 유발할 수 있으므로, 상기 범위 내로 발효제를 사용하는 것이 좋다. 그리고, 발효시 온도가 32℃ 미만이거나 발효 시간이 45시간 미만이면 발효가 진행되지 않거나 발효가 불충분하게 수행되며, 발효 온도가 40℃를 초과하거나 발효시간이 60시간을 초과하면 발효가 너무 진행되어 발효물을 이용한 화장료의 효과가 오히려 감소하는 문제가 있을 수 있으므로 상기 발효 온도 및 시간 범위에서 발효를 수행하는 것이 좋다.In the distillation extract manufacturing process, steps 2-4 are a process of obtaining a fermented product obtained by fermenting the hot water extract obtained in steps 2-3, and preferably 2.0 to 5.0 parts by weight of a fermentation agent based on 100 parts by weight of the hot water extract. After mixing 2.2 to 4.0 parts by weight of fermentation agent, fermentation was performed at 32 to 40°C, preferably at 36 to 40°C, for 45 to 60 hours, preferably 46 to 52 hours, and then filtered to obtain a fermented product. It is a process. At this time, if the amount of the fermentation agent used is less than 2.0 parts by weight, there may be a problem that fermentation does not proceed well, and even if the amount of fermentation agent used exceeds 5.0 parts by weight, the speed of fermentation does not become faster, and the amount of fermented product obtained does not increase. Rather, cosmetics using the obtained fermented product may cause skin problems, so it is better to use the fermentation agent within the above range. In addition, if the temperature during fermentation is less than 32℃ or the fermentation time is less than 45 hours, fermentation does not proceed or the fermentation is insufficient. If the fermentation temperature exceeds 40℃ or the fermentation time exceeds 60 hours, the fermentation proceeds too much. Since there may be a problem that the effect of cosmetics using fermented products is reduced, it is recommended to perform fermentation within the above fermentation temperature and time range.
그리고, 상기 발효제는 막걸리 효모 및 영지버섯 균사체 및 상황버섯 균사체 1.5 ~ 3.0 : 1 중량비로, 바람직하게는 1.6 ~ 2.8 : 1 중량비로, 더욱 바람직하게는 1.8 ~ 2.5 : 1 중량비로 포함하는 것이 좋다.In addition, the fermentation agent is preferably comprised of makgeolli yeast, reishi mushroom mycelium, and mycelium of Sanghwang mushroom in a weight ratio of 1.5 to 3.0:1, preferably in a weight ratio of 1.6 to 2.8:1, and more preferably in a weight ratio of 1.8 to 2.5:1.
그리고, 상기 막걸리 효모는 일반적인 막걸리 제조에 사용되는 효모를 사용할 수 있으며, 바람직하게는 누룩 효소균을 사용할 수 있다.In addition, the makgeolli yeast can be a yeast used in general makgeolli production, and preferably yeast enzyme bacteria can be used.
또한, 상기 열수 추출물 100 중량부에 대하여, 설탕 0.30 ~ 1.00 중량부, 소금 0.05 ~ 0.35 중량부 및 감식초 0.10 ~ 0.50 중량부를, 바람직하게는 설탕 0.40 ~ 0.90 중량부, 소금 0.10 ~ 0.30 중량부 및 감식초 0.20 ~ 0.40 중량부를 더 투입하여 발효를 수행하여 바효물을 수득할 수 있다.In addition, based on 100 parts by weight of the hot water extract, 0.30 to 1.00 parts by weight of sugar, 0.05 to 0.35 parts by weight of salt, and 0.10 to 0.50 parts by weight of persimmon vinegar, preferably 0.40 to 0.90 parts by weight of sugar, 0.10 to 0.30 parts by weight of salt, and persimmon vinegar. Fermentation can be performed by adding 0.20 to 0.40 parts by weight to obtain the fermented product.
다음으로, 2-4단계는 2-3단계의 발효물을 진공 증류 추출공정을 수행하여 증류 추출물을 수득한 후, 여과하여 여과물을 수득함으로써, 화장료 성분인 복합 한약재 발효물의 증류 추출물을 제조하는 공정이다.Next, in steps 2-4, the fermented product of steps 2-3 is subjected to a vacuum distillation extraction process to obtain a distilled extract, and then filtered to obtain a filtrate, thereby producing a distilled extract of the fermented complex herbal medicine, which is a cosmetic ingredient. It's fair.
상기 진공 증류 추출공정은 발효물을 80 ~ 85℃에서 가열하면서 기화하여 맺히는 이슬만을 모으는 추출법인 노법으로 진공 증류 추출을 수행할 수 있다.The vacuum distillation extraction process can be carried out by vacuum distillation extraction, which is an extraction method that collects only the dew that forms by vaporizing the fermented product while heating it at 80 to 85 ° C.
[복합 한약재 발효물][Compound herbal medicine fermentation product]
본 발명의 화장료 조성 중 하나인 복합 한약재 발효물은 앞서 설명한 증류 추출물과 달리, 진공 증류 추출 공정을 수행하지 않으며, 열수 추출 조건을 달리하여 제조한 발효물이다.The fermented complex herbal medicine, which is one of the cosmetic compositions of the present invention, is a fermented product prepared under different hot water extraction conditions, unlike the distilled extract described above, without performing a vacuum distillation extraction process.
좀 더 구체적으로 설명하면, 복합 한약재 발효물은, 상기 복합 한약재 및 물을 혼합한 후, 저온 열처리하는 2-1단계; 저온 열처리물을 여과한 후 냉각 처리하여 저온 열수 추출물을 수득하는 2-2단계; 저온 열수 추출물에 막걸리 효모 및 영지버섯 균사체 또는 상황버섯 균사체을 포함하는 발효제를 혼합한 후, 발효시킨 후, 여과하여 발효물을 수득하는 2-3단계; 및 수득한 발효물을 열처리하여 발효물을 사멸시킨 후, 여과 처리한 여과물을 수득하는 2-4단계;를 포함하는 공정을 수행하여 제조할 수 있다.To be more specific, the fermented composite herbal medicine is prepared by mixing the composite herbal medicine and water, followed by low-temperature heat treatment in step 2-1; Step 2-2 of filtering the low-temperature heat-treated product and then cooling it to obtain a low-temperature hot water extract; Steps 2-3 of mixing the low-temperature hot water extract with a fermentation agent containing makgeolli yeast and reishi mushroom mycelium or mycelium of Sanghwang mushroom, fermenting it, and then filtering to obtain a fermented product; and steps 2-4 of heat-treating the obtained fermented product to kill it and then obtaining a filtered filtrate.
복합 한약재 발효물 제조공정에 있어서, 상기 2-1단계의 저온 열처리는 상기 복합 한약재 및 물을 1 : 3.0 ~ 6.0 중량비로, 바람직하게는 1 : 3.5 ~ 5.0 중량비로 혼합한 후, 이를 40 ~ 60℃ 하에서 16 ~ 24시간 동안, 바람직하게는 50 ~ 62℃ 하에서 16 ~ 20시간 동안 수행한다. 이때, 물의 혼합량이 3 중량비 미만이면 저온 열수 추출물량이 너무 적은 문제가 있을 수 있고, 6 중량비를 초과하면 저온 열수 추출물 내 피부에 유익한 유효성분 농도가 너무 낮고, 추후 발효가 잘 되지 않을 수 있으므로 상기 범위 내로 물과 혼합하여 저온 열처리를 수행하는 것이 좋다.In the manufacturing process of fermented composite herbal medicine, the low-temperature heat treatment in step 2-1 is performed by mixing the composite herbal medicine and water at a weight ratio of 1:3.0 to 6.0, preferably 1:3.5 to 5.0, and then mixing the composite herbal medicine and water in a weight ratio of 40 to 60. It is performed at ℃ for 16 to 24 hours, preferably at 50 to 62℃ for 16 to 20 hours. At this time, if the mixing amount of water is less than 3 weight ratio, there may be a problem that the amount of low-temperature hot water extract is too small, and if it exceeds 6 weight ratio, the concentration of active ingredients beneficial to the skin in the low-temperature hot water extract is too low, and fermentation may not proceed well in the future, so it should be within the above range. It is recommended to perform low-temperature heat treatment by mixing it with water.
복합 한약재 발효물 제조공정에 있어서, 2-2 단계는 2-1단계의 저온 열처리를 수행하여 수득한 저온 열처리물을 여과 및 냉각 처리하여 저온 열수 추출물을 수득하는 공정이며, 이때 여과 방법은 일반적인 방법으로 수행할 수 있으며, 여과된 저온 열수 추출물 내 이물질, 잔여물 등 고형물을 포함하지 않으면 된다.In the manufacturing process of fermented complex herbal medicine, step 2-2 is a process of obtaining a low-temperature hot water extract by filtering and cooling the low-temperature heat-treated product obtained by performing the low-temperature heat treatment in step 2-1. In this case, the filtration method is a general method. It can be performed as long as it does not contain solid substances such as foreign substances and residues in the filtered low-temperature hydrothermal extract.
복합 한약재 발효물 제조공정에 있어서, 2-3단계는 2-2단계에서 수득한 저온 열수 추출물을 발효시킨 발효물을 수득하는 공정으로서, 상기 열수 추출물 100 중량부에 대하여, 발효제 2.0 ~ 5.0 중량부를, 바람직하게는 발효제 2.2 ~ 4.0 중량부를 혼합한 후, 32 ~ 40℃ 하에서, 바람직하게는 36 ~ 40℃ 하에서, 45 ~ 60시간 동안, 바람직하게는 46 ~ 52시간 동안 발효시킨 후, 여과하여 발효물을 수득하는 공정이다. 이때, 상기 발효제의 사용량이 2.0 중량부 미만이면 발효가 잘 진행되지 않는 문제가 있을 수 있고, 발효제 사용량이 5.0 중량부를 초과하더라도 발효 진행 속도가 더 빨라지지 않으며, 수득되는 발효물 양이 증가하지 않으며, 오히려 수득된 발효물을 이용한 화장료가 피부 트러블을 유발할 수 있으므로, 상기 범위 내로 발효제를 사용하는 것이 좋다. 그리고, 발효시 온도가 32℃ 미만이거나 발효 시간이 45시간 미만이면 발효가 진행되지 않거나 발효가 불충분하게 수행되며, 발효 온도가 40℃를 초과하거나 발효시간이 60시간을 초과하면 발효가 너무 진행되어 발효물을 이용한 화장료의 효과가 오히려 감소하는 문제가 있을 수 있으므로 상기 발효 온도 및 시간 범위에서 발효를 수행하는 것이 좋다.In the process of manufacturing a fermented product of a complex herbal medicine, steps 2-3 are a process of obtaining a fermented product obtained by fermenting the low-temperature hot water extract obtained in step 2-2, and 2.0 to 5.0 parts by weight of fermentation agent is added to 100 parts by weight of the hot water extract. , preferably after mixing 2.2 to 4.0 parts by weight of fermentation agent, fermented at 32 to 40°C, preferably at 36 to 40°C for 45 to 60 hours, preferably 46 to 52 hours, then filtered and fermented. This is the process of obtaining water. At this time, if the amount of the fermentation agent used is less than 2.0 parts by weight, there may be a problem that fermentation does not proceed well, and even if the amount of fermentation agent used exceeds 5.0 parts by weight, the speed of fermentation does not become faster, and the amount of fermented product obtained does not increase. Rather, cosmetics using the obtained fermented product may cause skin problems, so it is better to use the fermentation agent within the above range. In addition, if the temperature during fermentation is less than 32℃ or the fermentation time is less than 45 hours, fermentation does not proceed or the fermentation is insufficient. If the fermentation temperature exceeds 40℃ or the fermentation time exceeds 60 hours, the fermentation proceeds too much. Since there may be a problem that the effect of cosmetics using fermented products is reduced, it is recommended to perform fermentation within the above fermentation temperature and time range.
그리고, 상기 발효제는 막걸리 효모 및 영지버섯 균사체 또는 상황버섯 균사체 1.5 ~ 3.0 : 1 중량비로, 바람직하게는 1.6 ~ 2.8 : 1 중량비로, 더욱 바람직하게는 1.8 ~ 2.5 : 1 중량비로 포함하는 것이 좋다.In addition, the fermentation agent is preferably comprised of makgeolli yeast and reishi mushroom mycelium or mycelium Sanghwang mushroom in a weight ratio of 1.5 to 3.0:1, preferably in a weight ratio of 1.6 to 2.8:1, and more preferably in a weight ratio of 1.8 to 2.5:1.
상기 막걸리 효모 및/또는 영지버섯 균사체 또는 상황버섯 균사체는 앞서 설명한 증류 추출물 제조공정의 발효 공정에 사용하는 막걸리 효모, 영지버섯 균사체 또는 상황버섯 균사체와 동일하다.The makgeolli yeast and/or reishi mushroom mycelium or Sanghwang mushroom mycelium are the same as the makgeolli yeast, reishi mushroom mycelium, or Sanghwang mushroom mycelium used in the fermentation process of the distilled extract manufacturing process described above.
또한, 상기 열수 추출물 100 중량부에 대하여, 설탕 0.30 ~ 1.00 중량부, 소금 0.05 ~ 0.35 중량부 및 감식초 0.10 ~ 0.50 중량부를, 바람직하게는 설탕 0.40 ~ 0.90 중량부, 소금 0.10 ~ 0.30 중량부 및 감식초 0.20 ~ 0.40 중량부를 더 투입하여 발효를 수행하여 발효물을 수득할 수 있다.In addition, based on 100 parts by weight of the hot water extract, 0.30 to 1.00 parts by weight of sugar, 0.05 to 0.35 parts by weight of salt, and 0.10 to 0.50 parts by weight of persimmon vinegar, preferably 0.40 to 0.90 parts by weight of sugar, 0.10 to 0.30 parts by weight of salt, and persimmon vinegar. Fermented product can be obtained by performing fermentation by adding 0.20 to 0.40 parts by weight.
다음으로, 복합 한약재 발효물 제조공정에 있어서, 2-4단계는 수득한 발효물을 진공 열처리하여 추출물을 수득한 후, 이를 여과 처리하여 여과물을 수득함으로써, 복합 한약재 발효물을 수득하는 공정이다. 이때, 진공 열처리는 수득한 발효물을 82 ~ 95℃, 바람직하게는 85 ~ 90℃에서 진공 가열하여 수행할 수 있다.Next, in the process for producing a fermented compound herbal medicine, steps 2-4 are a process of obtaining a fermented compound herbal medicine by vacuum heat treating the obtained fermented product to obtain an extract and then filtering the obtained extract to obtain a filtrate. . At this time, vacuum heat treatment can be performed by vacuum heating the obtained fermented product at 82 to 95°C, preferably 85 to 90°C.
본 발명의 화장료 제조공정에 있어서, 3단계는 앞서 설명한 방법으로 제조한 복합 한약재 발효물의 증류 추출물 및 복합 한약재 발효물을 혼합한 혼합액을 화장료로서 제조하는 공정이다.In the cosmetic manufacturing process of the present invention, step 3 is a process of producing a cosmetic by mixing the distilled extract of the complex herbal medicine fermentation product and the complex herbal medicine fermentation product prepared by the method described above.
상기 혼합액은 본 발명의 화장료를 이용하여 제조하고자 하는 화장품의 종류에 따라 적절하게 혼합하여 사용할 수 있고, 바람직하게는 상기 혼합액은 복합 한약재 발효물 10 ~ 40 중량% 및 나머지 잔량의 상기 복합 한약재 발효물의 증류 추출물을 포함하는 범위 내에서 조절하여 사용할 수 있다.The mixed solution can be appropriately mixed and used depending on the type of cosmetic to be manufactured using the cosmetic of the present invention. Preferably, the mixed solution contains 10 to 40% by weight of the composite herbal medicine fermentation product and the remaining amount of the composite herbal medicine fermentation product. It can be used by adjusting it within the range including distilled extract.
본 발명의 화장료가 크림 타입 화장품의 화장료로 사용되는 경우, 복합 한약재 발효물 10 ~ 20 중량% 및 나머지 잔량의 상기 복합 한약재 발효물의 증류 추출물을, 바람직하게는 복합 한약재 발효물 10 ~ 15 중량% 및 나머지 잔량의 상기 복합 한약재 발효물의 증류 추출물을 혼합하여 사용하는 것이 좋다.When the cosmetic of the present invention is used as a cosmetic for cream-type cosmetics, 10 to 20% by weight of the complex herbal medicine fermentation and the remaining amount of the distilled extract of the complex herbal medicine fermentation, preferably 10 to 15% by weight of the complex herbal medicine fermentation and It is recommended to use the remaining amount of the distilled extract of the fermented complex herbal medicine mixed with it.
크림 타입 화장품의 바람직한 일례를 들면, 하기 표 1과 같다.A preferred example of cream-type cosmetics is shown in Table 1 below.
100 중량%remaining balance
100% by weight
또한, 본 발명의 화장료가 스킨 타입 화장품의 화장료로 사용되는 경우, 복합 한약재 발효물 20 ~ 40 중량% 및 나머지 잔량의 상기 복합 한약재 발효물의 증류 추출물을, 바람직하게는 복합 한약재 발효물 20 ~ 35 중량% 및 나머지 잔량의 상기 복합 한약재 발효물의 증류 추출물을 혼합하여 사용하는 것이 좋다.In addition, when the cosmetic of the present invention is used as a cosmetic for skin type cosmetics, 20 to 40% by weight of the fermented complex herbal medicine and the remaining amount of the distilled extract of the fermented complex herbal medicine are used, preferably 20 to 35% by weight of the fermented complex herbal medicine. It is recommended to use a mixture of % and the remaining amount of distilled extract of the fermented complex herbal medicine.
스킨 타입 화장품의 바람직한 일례를 들면, 하기 표 2와 같다.A preferred example of skin type cosmetics is shown in Table 2 below.
100 중량%remaining balance
100% by weight
앞서 설명한 방법으로 제조한 본 발명의 여드름 개선 화장료는 피부 트러블이 없으면서도, 진정, 보습 효과가 우수하고, 피부미백 및 주름 개선 효과도 있으면서 여드름 개선 효과가 우수한 바, 스킨, 로션 등의 다양한 제형의 피부용 기능성 화장품의 화장료로 사용하기 적합하다.The acne-improving cosmetic of the present invention prepared by the method described above is available in various formulations such as bars, skins, and lotions that do not cause skin trouble, have excellent soothing and moisturizing effects, have skin whitening and wrinkle-improving effects, and have excellent acne-improving effects. It is suitable for use as a cosmetic ingredient in functional cosmetics for skin.
이하, 실시예를 통하여 본 발명을 더욱 구체적으로 설명하기로 하지만, 하기 실시예가 본 발명의 범위를 제한하는 것은 아니며, 이는 본 발명의 이해를 돕기 위한 것으로 해석되어야 할 것이다.Hereinafter, the present invention will be described in more detail through examples. However, the following examples do not limit the scope of the present invention, and should be interpreted to aid understanding of the present invention.
[실시예][Example]
준비예 1-1 : 복합 한약재 발효물의 증류 추출물의 제조Preparation Example 1-1: Preparation of distilled extract of fermented complex herbal medicine
비파나무 잎 15 중량%, 당잔대 잎 및 뿌리 15 중량%, 새싹보리 15 중량%, 삼백초 10 중량%, 개똥쑥 씨 10% 중량%, 티트리 잎 5 중량% 및 나머지 잔량의 황칠나무를 혼합한 혼합물을 초음파 기기에서 초음파 세척한 후, 건조하여 복합 한약재를 준비하였다. 그리고, 상기 황칠나무는 황칠나무의 잎, 줄기 및 열매의 혼합물을 포함한다.A mixture of 15% by weight of loquat leaves, 15% by weight of Tangerine leaves and roots, 15% by weight of sprouted barley, 10% by weight of Trifolium primrose, 10% by weight of Artemisia seeds, 5% by weight of tea tree leaves and the remaining amount of Hwangchil tree. The mixture was ultrasonic washed in an ultrasonic device and then dried to prepare a composite herbal medicine. And, the Hwangchil tree includes a mixture of leaves, stems and fruits of the Hwangchil tree.
상기 복합 한약재 중 뿌리, 줄기와 같이 단단한 한약재와 잎, 열매와 같인 연한 한약재를 나눈 후, 단단한 부위의 한약재는 87 ~ 90℃ 하에서 약 4시간 찜 처리를 수행하였다. 또한, 연한 부위의 한약재는80 ~ 83℃ 하에서 약 2시간 동안 찜 처리를 수행하였다. 그 후, 찜 처리한 단단한 부위 및 연한 부위 한약재를 섞어서 찜 처리한 복합 한약재를 준비하였다.Among the complex herbal medicines, after dividing them into hard herbal medicines such as roots and stems and soft herbal medicines such as leaves and fruits, the hard herbal medicines were steamed at 87 to 90°C for about 4 hours. In addition, the herbal medicine in the soft area was steamed at 80 to 83°C for about 2 hours. Afterwards, the steamed complex herbal medicine was prepared by mixing the steamed hard part and soft part herbal medicine.
다음으로, 상기 찜 처리한 복합 한약재를 물과 1 : 3.1 중량비로 혼합한 혼합액을 90℃ 하에서 12시간 동안 열수 공정(열처리)을 수행한 후, 여과 및 냉각 처리하여 열수 추출물을 수득하였다.Next, the steamed composite herbal medicine mixed with water at a weight ratio of 1:3.1 was subjected to a hydrothermal process (heat treatment) at 90°C for 12 hours, followed by filtration and cooling to obtain a hydrothermal extract.
다음으로, 열수 추출물 약 4kg을 발효조에 투입한 다음, 막걸리 효모인 누룩 효소균 및 영지버섯 균사체를 2 : 1 중량비로 포함하는 발효제, 설탕, 소금, 감식초를 발효조에 투입하였다. 이때, 발효제의 사용량은 발효조에 투입된 열수 추출물 100 중량부에 대하여, 2.55 중량부로 투입하였다. 또한, 상기 열수 추출물 100 중량부에 대하여, 설탕 0.60 중량부, 소금 0.150 중량부 및 감식초 0.260 중량부를 투입하였다.Next, about 4 kg of hot water extract was added to the fermentation tank, and then a fermenting agent containing makgeolli yeast, yeast enzyme bacteria, and reishi mushroom mycelium at a weight ratio of 2:1, sugar, salt, and persimmon vinegar were added to the fermentation tank. At this time, the amount of fermentation agent used was 2.55 parts by weight based on 100 parts by weight of the hot water extract added to the fermenter. Additionally, with respect to 100 parts by weight of the hot water extract, 0.60 parts by weight of sugar, 0.150 parts by weight of salt, and 0.260 parts by weight of persimmon vinegar were added.
그리고, 38℃ 하에서 52시간 동안 발효 공정을 수행한 다음, 여과하여 발효물을 수득하였다.Then, the fermentation process was performed at 38°C for 52 hours and then filtered to obtain a fermented product.
다음으로, 상기 발효물을 90℃로 진공 가열하여, 수득된 증류물을 수득하는 진공 증류 추출 공정을 수행한 후, 여과하여 증류 추출물인 복합 한약재 발효물의 증류 추출물을 제조하였고, 제조한 증류 추출물은 냉장(2 ~ 3℃) 보관하였다.Next, the fermented product was vacuum heated to 90°C, a vacuum distillation extraction process was performed to obtain the obtained distillate, and then filtered to prepare a distilled extract of the complex herbal medicine fermentation, and the prepared distilled extract was Stored refrigerated (2 ~ 3℃).
준비예 1-2 ~ 1-3 및 비교준비예 1-1 ~ 1-5Preparation Examples 1-2 to 1-3 and Comparative Preparation Examples 1-1 to 1-5
상기 준비예 1-1과 동일한 방법으로 복합 한약재 발효물의 증류 추출물을 제조하되, 하기 표 3과 같이 복합 한약재 내 한약재 함량을 달리하거나, 발효 조건을 달리하여 증류 추출물을 각각 제조하여 준비예 1-2 ~ 1-3 및 비교준비예 1-1 ~ 1-5를 각각 실시하였다.A distilled extract of the fermented composite herbal medicine was prepared in the same manner as in Preparation Example 1-1, but the content of the herbal medicine in the composite herbal medicine was varied or the fermentation conditions were changed as shown in Table 3 below to prepare the distilled extract, respectively, as shown in Preparation Example 1-2. ~1-3 and Comparative Preparation Examples 1-1 to 1-5 were carried out, respectively.
1-1Preparation example
1-1
1-2Preparation example
1-2
1-3Preparation example
1-3
준비예
1-1comparison
Preparation example
1-1
준비예
1-2comparison
Preparation example
1-2
준비예
1-3comparison
Preparation example
1-3
준비예
1-4comparison
Preparation example
1-4
준비예
1-5comparison
Preparation example
1-5
한약재
(중량%)complex
herbal medicine
(weight%)
준비예 2 : 복합 한약재 발효물 제조Preparation Example 2: Preparation of fermented complex herbal medicine
준비예 1-1과 동일한 조성 및 함량의 한약재를 혼합, 세척 및 건조하여 복합 한약재를 준비하였다.A composite herbal medicine was prepared by mixing, washing and drying herbal medicines with the same composition and content as in Preparation Example 1-1.
다음으로, 상기 복합 한약재를 물과 1 : 4.5 중량비로 혼합한 혼합액을 50℃ 하에서 18시간 동안 열수 공정(열처리)을 수행한 후, 여과 및 냉각 처리하여 저온 열수 추출물을 수득하였다.Next, the mixed herbal medicine mixed with water at a weight ratio of 1:4.5 was subjected to a hydrothermal process (heat treatment) at 50°C for 18 hours, followed by filtration and cooling to obtain a low-temperature hydrothermal extract.
다음으로, 열수 추출물 약 4kg을 발효조에 투입한 다음, 막걸리 효모인 누룩 효소균 및 영지버섯 균사체를 2 : 1 중량비로 포함하는 발효제, 설탕, 소금, 감식초를 발효조에 투입하였다. 이때, 발효제의 사용량은 발효조에 투입된 열수 추출물 100 중량부에 대하여, 2.56 중량부로 투입하였다. 또한, 상기 열수 추출물 100 중량부에 대하여, 설탕 0.62 중량부, 소금 0.145 중량부 및 감식초 0.252 중량부를 투입하였다.Next, about 4 kg of hot water extract was added to the fermentation tank, and then a fermenting agent containing makgeolli yeast, yeast enzyme bacteria, and reishi mushroom mycelium at a weight ratio of 2:1, sugar, salt, and persimmon vinegar were added to the fermentation tank. At this time, the amount of fermentation agent used was 2.56 parts by weight based on 100 parts by weight of the hot water extract added to the fermenter. Additionally, with respect to 100 parts by weight of the hot water extract, 0.62 parts by weight of sugar, 0.145 parts by weight of salt, and 0.252 parts by weight of persimmon vinegar were added.
그리고, 38℃ 하에서 48시간 동안 발효 공정을 수행한 다음, 여과하여 발효물을 수득하였고, 이를 냉장(2 ~ 3℃) 보관하였다.Then, the fermentation process was performed at 38°C for 48 hours, then filtered to obtain a fermented product, which was stored in refrigeration (2 to 3°C).
실시예 1 : 여드름 개선 화장료의 제조Example 1: Preparation of acne improving cosmetics
상기 준비예 2에서 제조한 복합 한약재 발효물 30 중량% 및 상기 준비예 1-1에서 증류 추출물 70중량%를 균질기에서 혼합하여 화장료를 제조하였다.A cosmetic was prepared by mixing 30% by weight of the fermented complex herbal medicine prepared in Preparation Example 2 and 70% by weight of the distilled extract from Preparation Example 1-1 in a homogenizer.
실시예 2 ~ 5 및 비교예 1 ~ 5Examples 2 to 5 and Comparative Examples 1 to 5
상기 실시예 1과 동일한 방법으로 화장료를 제조하되, 하기 표 4와 같이 복합 한약재 발효물 및 증류 추출물을 달리하여 화장료를 각각 제조하여, 실시예 2 ~ 5 및 비교예 1 ~ 5를 각각 실시하였다.Cosmetics were prepared in the same manner as in Example 1, but with different fermented herbal medicines and distilled extracts as shown in Table 4 below, and Examples 2 to 5 and Comparative Examples 1 to 5 were performed, respectively.
(준비예 2) 함량Fermented complex herbal medicine
(Preparation Example 2) Content
증류 추출물Fermented complex herbal medicine
distilled extract
실험예 1 : 피부 세포 독성 실험Experimental Example 1: Skin cytotoxicity experiment
RAW 264.7 세포(한국세포주은행)를 소태아혈청(fetal bovine serum) 10% 첨가한 DMEM(Gibco) 배지에 2×105 세포수/mL의 농도로 현탁하여 200㎕씩 96 웰 플레이트(96-well plate)에 접종하여 부착하였다. 그 후에 실시예 1 ~ 5 및 비교예 1 ~ 7에서 제조한 화장료를 각각 1000㎍/㎖의 농도로 처리하고 20시간 배양하였다. 5mg/㎖의 MTT 용액을 웰당 20㎕씩 첨가한 후 4시간을 더 배양하였다. 상등액을 제거한 후, DMSO를 100㎕씩 첨가한 다음, 570nm에서 흡광도를 측정하였다. 세포생존률은 PBS를 처리한 음성 대조군을 100%로 하여 하기 식 1에 따라 계산하였으며, 그 결과를 하기 표 5에 나타내었다.RAW 264.7 cells (Korea Cell Line Bank) were suspended at a concentration of 2×10 5 cells/mL in DMEM (Gibco) medium supplemented with 10% fetal bovine serum and plated in 96-well plates (200 ㎕ each). plate) and attached. Afterwards, the cosmetics prepared in Examples 1 to 5 and Comparative Examples 1 to 7 were each treated at a concentration of 1000 μg/ml and cultured for 20 hours. 20 μl of 5 mg/ml MTT solution was added per well and cultured for an additional 4 hours. After removing the supernatant, 100 μl of DMSO was added, and the absorbance was measured at 570 nm. Cell viability was calculated according to Equation 1 below, taking the negative control group treated with PBS as 100%, and the results are shown in Table 5 below.
[식 1][Equation 1]
세포생존율(%) = (화장료 처리군 흡광도 값/음성 대조군 흡광도 값)×100%Cell viability (%) = (cosmetic treatment group absorbance value/negative control group absorbance value) x 100%
상기 표 5의 세포 생존율 측정 결과를 살펴보면, 전반적으로 실시예 및 비교예 모두 피부 세포에 대한 세포 독성이 없는 것으로 나타났다. 다만, 발효제를 막걸리 효모 및 영지버섯 균사체를 1 : 5 중량비로 사용했던 비교준비예 1-5의 화장료를 사용한 비교예 3, 및 복합 한약제 발효물을 40 중량% 초과한 50 중량% 사용한 화장료인 비교예 7의 경우, 다소 피부 세포 생존율이 낮게 나왔으며, 이는 다른 화장료에 비해 상대적으로 피부 독성이 다소 있다고 판단된다.Looking at the cell viability measurement results in Table 5 above, overall, both Examples and Comparative Examples showed no cytotoxicity to skin cells. However, Comparative Example 3 using the cosmetics of Comparative Preparation Examples 1-5 in which makgeolli yeast and reishi mushroom mycelium were used as fermentation agents at a weight ratio of 1:5, and Comparative Example 3 using cosmetics using 50% by weight, exceeding 40% by weight, of fermented complex herbal medicine. In the case of Example 7, the skin cell survival rate was somewhat low, which is considered to be relatively more toxic to the skin than other cosmetics.
실험예 2 : 티로시나아제 저해 효과 통한 피부미백 효과 실험Experimental Example 2: Experiment on skin whitening effect through tyrosinase inhibition effect
상기 실시예 및 비교예에서 제조한 화장료의 티로시나아제 저해 효과를 분석하기 위하여, 버섯 유래의 티로시나아제 (Sigma)를 이용하여 화장료가 L L-티로신을 L-DOPA(L-3,4-dihydroxy phenylalanine)로 전환되는 것을 저해하는 효능을 분석하였다.In order to analyze the tyrosinase inhibitory effect of the cosmetics prepared in the above Examples and Comparative Examples, mushroom-derived tyrosinase (Sigma) was used to determine whether the cosmetics were able to convert L L-tyrosine into L-DOPA (L-3,4- The efficacy of inhibiting conversion to dihydroxy phenylalanine was analyzed.
L-티로신에 대한 티로시나아제 저해 검정을 위하여, 120μl 0.1M 인산 나트륨 완충용액 (pH 6.5), 20μl 1,000unit/mL 티로시나아제, 20μl 시료를 각각 96 웰 마이크로플레이트에 첨가하여 상온에서 10분 동안 반응한 다음, 40μl 1.5mM L-티로신을 첨가하여, 25℃에서 10분 동안 490nm에서 흡광도를 측정하였다.For the tyrosinase inhibition assay for L-tyrosine, 120 μl 0.1M sodium phosphate buffer solution (pH 6.5), 20 μl 1,000 unit/mL tyrosinase, and 20 μl sample were each added to a 96-well microplate and incubated at room temperature for 10 minutes. After the reaction, 40 μl of 1.5mM L-tyrosine was added, and the absorbance was measured at 490 nm for 10 minutes at 25°C.
음성대조군(N-control)은 증류수를 이용하였고, 양성대조군(P-control)은 코직산(KA, Sigma), 실험구는 화장료 함량으로 20, 40, 80, 100μg/ml 농도별로 분석하였으며, 측정된 IC50(half maximal inhibitory concentration)을 값을 하기 표 6에 나타내었다.Distilled water was used as the negative control group (N-control), kojic acid (KA, Sigma) was used as the positive control group (P-control), and the experimental group was analyzed for cosmetic content by concentration of 20, 40, 80, and 100 μg/ml, and the measured IC The value of 50 (half maximal inhibitory concentration) is shown in Table 6 below.
상기 표 6의 티로시나아제 저해능 측정결과를 살펴보면, 실시예 1 ~ 5는 68mg/ml 이하의 농도에서 IC50을 가짐을 확인할 수 있었다.Looking at the tyrosinase inhibition activity measurement results in Table 6 above, it was confirmed that Examples 1 to 5 had an IC 50 at a concentration of 68 mg/ml or less.
이에 반해, 비교예 1 ~ 5의 경우, 실시예 1 ~ 5와 비교할 때, 많은 상대적으로 높은 농도에서 IC50을 가지며, 실시예와 비교할 때, 티로시나아제 저해 효과가 상대적으로 저조함을 보였다.On the other hand, Comparative Examples 1 to 5 had IC 50 at relatively high concentrations compared to Examples 1 to 5, and showed a relatively low tyrosinase inhibitory effect compared to the Examples.
또한, 발효제로서 영지버섯 균사체를 5 중량비 사용한 비교예 5의 경우, 다른 실시예와 비교할 때 오히려 티로시나아제 저해 효과가 상대적으로 떨어졌다.In addition, in the case of Comparative Example 5, in which reishi mushroom mycelium was used at a weight ratio of 5 as a fermenting agent, the tyrosinase inhibitory effect was relatively poor compared to other examples.
그리고, 화장료 내 복합 한약재 복합물을 10 중량% 미만으로 사용한 비교예 6(5 중량%)의 경우, 티로시나아제 저해 효과가 크게 부족해지는 문제가 있었다.In addition, in the case of Comparative Example 6 (5 wt%), in which less than 10 wt% of the herbal medicine complex in the cosmetic was used, there was a problem that the tyrosinase inhibitory effect was significantly insufficient.
복합 한약제 발효물을 40 중량% 초과한 50 중량% 사용한 화장료인 비교예 7(50 중량%)의 경우, 실시예 5와 비교할 때, 티로시나아제 저해 효과가 오히려 다소 감소하였으며, 실험예 1에서 피부 세포 독성이 다소 있었는 바, 복합 한약재 발효물 40 중량% 초과 사용하는 것은 과량 사용으로 오히려 화장료의 효과가 감소한다는 결과를 도출할 수 있었다.In the case of Comparative Example 7 (50% by weight), which is a cosmetic using 50% by weight of the fermented herbal medicine exceeding 40% by weight, the tyrosinase inhibitory effect was somewhat reduced compared to Example 5, and in Experimental Example 1, the skin As there was some cytotoxicity, it was concluded that using more than 40% by weight of the fermented complex herbal medicine actually reduces the effectiveness of the cosmetic due to excessive use.
이를 통해서, 본 발명의 화장료가 티로시나아제 저해 효과를 통한 미백 효과를 가질 수 있음을 확인할 수 있었다.Through this, it was confirmed that the cosmetic of the present invention can have a whitening effect through a tyrosinase inhibitory effect.
실험예 3 : 피부주름 개선 효과 측정Experimental Example 3: Measurement of skin wrinkle improvement effect
상기 실시예 및 비교예에서 제조한 화장료의 피부주름 개선 효과를 확인하기 위하여, 하기와 같은 방법으로 엘라스타아제(elastase) 활성 억제를 측정하였고, 그 결과를 하기 표 7에 나타내었다.In order to confirm the skin wrinkle improvement effect of the cosmetics prepared in the above Examples and Comparative Examples, the inhibition of elastase activity was measured in the following manner, and the results are shown in Table 7 below.
측정방법은 96웰 플레이트에 100mM Tris-HCl 완충액(pH 8.0) 100㎕를 분주하고, 상기 화장료를 동일 분량으로 가한 다음, 2.9mM의 N-Succinyl-(Ala)3-pnitroanilide 20㎕를 분주하였다. 이어, 0.2unit으로 조제한 엘라스타아제 효소액 15㎕를 가하여 혼합하고, 25℃에서 20분 동안 반응시켰다. 상기 반응물을 얼음에서 5분간 방치하여 반응을 종료시키고, 410nm 파장의 microplate reader를 사용하여 흡광도를 측정하고 하기 식 2에 대입하여 엘라스타아제 활성율을 측정하였고, 티로시나아제의 최대 억제활성의 50%를 나타낼 수 있는 농도(IC50)를 산출하였다(표 5). 이때, 양성 대조군은 우르솔릭산(ursolic acid)을 첨가한 반응물을 사용하고, 음성대조군으로 증류수를 사용하였다.The measurement method was to dispense 100㎕ of 100mM Tris-HCl buffer (pH 8.0) into a 96-well plate, add the above cosmetics in equal amounts, and then dispense 20㎕ of 2.9mM N-Succinyl-(Ala)3-pnitroanilide. Next, 15 ㎕ of elastase enzyme solution prepared at 0.2 units was added, mixed, and reacted at 25°C for 20 minutes. The reaction was terminated by leaving the reaction product on ice for 5 minutes, the absorbance was measured using a microplate reader with a wavelength of 410 nm, and the elastase activity rate was measured by substituting it into Equation 2 below, and the maximum inhibitory activity of tyrosinase was 50%. The concentration (IC 50 ), which can represent %, was calculated (Table 5). At this time, a reaction product to which ursolic acid was added was used as a positive control, and distilled water was used as a negative control.
[식 2][Equation 2]
엘라스타아제 활성율(%) = 1-{(시료액 흡광도-음성대조군 흡광도)/음성대조군 흡광도×100(%)}Elastase activity rate (%) = 1-{(sample solution absorbance-negative control absorbance)/negative control absorbance×100(%)}
상기 표 7의 엘라스타아제 저해능 측정결과를 살펴보면, 실시예 1 ~ 5는 양성대조군 보다는 다소 낮지만, 전반적으로 낮은 농도에서 IC50을 가짐을 확인할 수 있었다.Looking at the elastase inhibition activity measurement results in Table 7 above, it was confirmed that Examples 1 to 5 had an IC 50 at an overall low concentration, although it was slightly lower than that of the positive control group.
이에 반해, 비교예 1 ~ 5의 경우, 실시예 1 ~ 5와 비교할 때, 많은 상대적으로 높은 농도에서 IC50을 가지며, 실시예와 비교할 때, 엘라스타아제 저해 효과가 상대적으로 저조함을 보였다.On the other hand, Comparative Examples 1 to 5 had IC 50 at relatively high concentrations compared to Examples 1 to 5, and compared to Examples, the elastase inhibitory effect was relatively low.
또한, 발효제로서 영지버섯 균사체를 1 중량비로 너무 적게 또는 5 중량비로 과하게 사용한 비교예 4 및 비교예 5의 경우, 다른 실시예와 비교할 때 오히려 엘라스타아제 저해 효과가 상대적으로 떨어졌다.In addition, in the case of Comparative Examples 4 and 5, in which the reishi mushroom mycelium was used too little at a weight ratio of 1 or excessively at a weight ratio of 5 as a fermenting agent, the elastase inhibitory effect was relatively poor compared to other examples.
그리고, 화장료 내 복합 한약재 복합물을 10 중량% 미만으로 사용한 비교예 6(5 중량%)의 경우, 엘라스타아제 저해 효과가 크게 부족해지는 문제가 있었다.In addition, in the case of Comparative Example 6 (5 wt%), in which less than 10 wt% of the herbal medicine complex in the cosmetic was used, there was a problem of a significant lack of elastase inhibitory effect.
복합 한약제 발효물을 40 중량% 초과한 50 중량% 사용한 화장료인 비교예 7(50 중량%)의 경우, 실시예 5와 비교할 때, 엘라스타아제 저해 효과가 오히려 다소 감소하였다.In the case of Comparative Example 7 (50% by weight), which is a cosmetic using more than 40% by weight of the complex fermented herbal medicine (50% by weight), the elastase inhibitory effect was somewhat reduced compared to Example 5.
이를 통해서, 본 발명의 화장료가 엘라스타아제 저해 효과를 통한 피부주름 개선 효과를 가질 수 있음을 확인할 수 있었다.Through this, it was confirmed that the cosmetic of the present invention can have the effect of improving skin wrinkles through the elastase inhibitory effect.
실험예 4 : 여드름 억제 평가Experimental Example 4: Acne inhibition evaluation
5α-리덕타아제는 피지 과잉생산을 유발하여 여드름 증상을 악화시키는 것을 알려져 있다.5α-reductase is known to worsen acne symptoms by causing sebum overproduction.
상기 실시예 1과 비교예 3에서 제조한 화장료의 5α-리덕타아제 활성 억제력을 확인하기 위해 사용된 5α-리덕타아제를 얻는 과정은 0 ~ 2℃에서 수행하였다. 본 시험에 사용된 쥐는 스파라그-돌리(Sprague-Dawley)계로서 300 ~ 312g의 무게를 갖는 성숙한 암컷(8주령)을 디에틸에테르로 호흡 마취하고 경추탈골하여 죽인 후, 해부하여 간을 적출하고 완충액(0.13M 수크로오스, 10mM Tris-HCl, 40ul/L 2-머캅토에탄올)으로 세척 후 완충액에 넣어 분쇄기로 현탁액을 조제하였다. 상기 현탁액에서 5α-리덕타아제를 분리하기 위하여 원심분리(105,000g, 1hr,4℃)한 후 상층액에서 취하여 -70℃에서 보관하여 사용하였다.The process of obtaining 5α-reductase used to confirm the inhibitory ability of the cosmetics prepared in Example 1 and Comparative Example 3 to inhibit 5α-reductase activity was performed at 0 to 2°C. The rats used in this test were the Sprague-Dawley strain. Mature females (8 weeks old) weighing 300 to 312 g were anesthetized with diethyl ether, killed by cervical dislocation, and then dissected to remove the liver. After washing with buffer solution (0.13M sucrose, 10mM Tris-HCl, 40ul/L 2-mercaptoethanol), it was placed in buffer solution and a suspension was prepared using a grinder. To separate 5α-reductase from the suspension, it was centrifuged (105,000 g, 1 hr, 4°C), then taken from the supernatant and stored at -70°C for use.
5α-리덕타아제 활성억제 효과를 평가하기 위해 SUN ZU-YUE et al.(Indian Journal of Pharmacology, 1998)가 사용한 방법을 사용하였다. 상기와 같은 방법으로 얻은 상층액의 일부를 취하여 완충액 내에서 NADPH2 (조효소), 테스토스테론(기질), 추출물(저해제; inhibitor)과 반응시켜 조효소로 작용하는 NADPH2의 감소량의 변화를 UV 분광광도계(spectrophotometer)를 이용하여 340nm에서 측정하였다. 이 데이터를 이용하여 반응속도, 테스토스테론(기질), 추출물(저해제)이 관련된 Lineweaver-Burk Plot, Dixon Plot을 작성하였으며, 이를 토대로 Ki (저해상수)를 계산하였다. Ki는 반응속도 Vmax와 반포화상수 Km을 1/2로 만드는 저해제의 농도로서, 그 값이 작으면 작을수록 저해 효과가 뛰어남을 의미한다. 표 8은 실시예 1 화장료의 Ki 값과 대조군의 값을 나타낸다.To evaluate the effect of inhibiting 5α-reductase activity, the method used by SUN ZU-YUE et al. (Indian Journal of Pharmacology, 1998) was used. A portion of the supernatant obtained in the same manner as above was taken and reacted with NADPH 2 (coenzyme), testosterone (substrate), and extract (inhibitor) in the buffer solution, and the change in the amount of reduction of NADPH 2 , which acts as a coenzyme, was measured using a UV spectrophotometer ( It was measured at 340 nm using a spectrophotometer. Using this data, Lineweaver-Burk Plot and Dixon Plot related to reaction rate, testosterone (substrate), and extract (inhibitor) were created, and Ki (inhibition constant) was calculated based on this. Ki is the concentration of the inhibitor that reduces the reaction rate Vmax and the half saturation constant Km to 1/2. The smaller the value, the better the inhibitory effect. Table 8 shows the Ki values of the cosmetics of Example 1 and the values of the control group.
표 8의 측정 결과를 살펴보면, 양성대조군인 아젤라익산 보다 실시예 1의 화장료가 더 우수한 5α-리덕타아제 저해 효과가 있음을 확인할 수 있었다. 이에 반해, 비교예 3의 경우, 양성대조군 보다는 5α-리덕타아제 저해가 우수하나, 실시예 1과 비교할 때, 저해 효과가 크게 떨어지는 결과를 확인할 수 있었다.Looking at the measurement results in Table 8, it was confirmed that the cosmetic of Example 1 had a better 5α-reductase inhibition effect than azelaic acid, which was a positive control. On the other hand, in the case of Comparative Example 3, 5α-reductase inhibition was superior to that of the positive control group, but compared to Example 1, it was confirmed that the inhibitory effect was significantly reduced.
실험예 5 : 피지 생성 억제 평가Experimental Example 5: Evaluation of sebum production inhibition
실시예 1 화장료의 시험관내(in vitro) 상에서 직접적으로 피지 생성을 어느 정도 억제하는지 확인하고자 피지 생성(lipogenesis) 실험을 수행하였다. 인체 피지선 세포의 수득 및 일차 배양 방법은 실험예 4와 같으며, 계대배양시 본 실험을 위해 24 웰-플레이트(24 well-plate)를 이용하여 웰 당 2×105개 세포를 심었다. 24시간 배양하여 세포가 웰에 고착된 후, 웰에 실시예 1 화장료를 디메틸술폭사이드(dimethylsulfoxide: DMSO)에 분산시켜 최종 농도 0.05%(w/v)로 처리하여 72시간을 배양한 후, 생존한 세포의 수를 계산하고, 생성된 피지의 양을 메탄올:클로로포름 추출법을 이용하여 추출 및 측정하여 1×104 cell당 생성된 총 피지량을 비교하여 피지생성 억제 정도를 상대 비교하였고, 그 결과를 하기 표 9에 나타내었다. 피지의 추출 방법은 조보울리스(Zoboulis) 등(J. Invest. Dermatol., 1991; 24, 69-83)의 방법을 이용하였으며, 메탄올:클로로포름 추출단계, 초음파 파쇄단계, 필터링 단계, 질소 증발(nitrogen evaporation) 단계를 포함한다.Example 1 A lipogenesis experiment was performed to determine the extent to which cosmetics directly inhibit sebum production in vitro. The method of obtaining and primary culturing human sebaceous gland cells was the same as in Experimental Example 4, and for this experiment during subculture, 2×10 5 cells were planted per well using a 24 well-plate. After culturing for 24 hours and allowing the cells to adhere to the wells, the cosmetics of Example 1 were dispersed in dimethylsulfoxide (DMSO) and treated at a final concentration of 0.05% (w/v) in the wells. After culturing for 72 hours, survival occurred. The number of cells was calculated, the amount of sebum produced was extracted and measured using the methanol:chloroform extraction method, and the total amount of sebum produced per 1 × 10 4 cell was compared to compare the degree of sebum production inhibition, and the results were compared. It is shown in Table 9 below. The sebum extraction method used was the method of Zoboulis et al. (J. Invest. Dermatol., 1991; 24, 69-83), and included a methanol:chloroform extraction step, ultrasonic disruption step, filtering step, and nitrogen evaporation ( It includes a nitrogen evaporation step.
실험 결과, 실시예 1 화장료는 인체 피지선 세포의 피지생성을 저해하는 효과가 양성대조군에 비하여 높은 것으로 되었으며, 피지 생성 억제를 통한 여드름 예방 내지 개선 효과를 있는 기능성 화장품 소재로 사용하기 적합함을 확인할 수 있었다.As a result of the experiment, the cosmetic of Example 1 had a higher effect of inhibiting sebum production of human sebaceous gland cells than the positive control group, and it was confirmed that it is suitable for use as a functional cosmetic material that prevents or improves acne by suppressing sebum production. there was.
실험예 6 : 화장료 내 총폴리페놀, 총플로보노이드, 전자공여능, ABTS 양이온 라디칼 소거능 측정Experimental Example 6: Measurement of total polyphenols, total flavonoids, electron donating ability, and ABTS cation radical scavenging ability in cosmetics
실시예 1에서 제조한 화장료에 대한 리페놀, 플로보노이드, 전자공여능, ABTS 양이온 라디칼 소거능 측정을 ㈜순천바이오헬스케어연구센터에 의뢰하여 측정하였고, 그 결과를 하기 표 10 ~ 표 12에 나타내었다.Liphenol, flavonoid, electron donating ability, and ABTS cation radical scavenging ability of the cosmetic prepared in Example 1 were measured by requesting Suncheon Bio Healthcare Research Center Co., Ltd., and the results are shown in Tables 10 to 12 below. .
총폴리페놀 함량 측정은 AOAC의 FolinDenis 방법(Folin & Denis, 1912)을 수정하여 측정하였으며, 총플로보노이드 함량은 알루미늄 컬러메트릭법(Aluminum colorimetric method, Anna & Krystyna 2014)을 이용하여 측정하였다. 그리고, 전여공여능(DPPH radical scabenging acitivity)은 Blois 방법을 응용하여 측정하였으며, ABTS 양이온 라디칼 소거능은 ABTS cation radical decolorization assay에 의해 측정하였다.Total polyphenol content was measured by modifying AOAC's FolinDenis method (Folin & Denis, 1912), and total flavonoid content was measured using the aluminum colorimetric method (Anna & Krystyna 2014). Additionally, DPPH radical scavenging activity was measured using the Blois method, and ABTS cation radical scavenging activity was measured using ABTS cation radical decolorization assay.
b=샘플(n=3)의 ml당 퀘르세틴(Quercetin) 당량μg에 대한 표현임a=Expression of equivalent μg of gallic acid per ml of sample (n=3)
b=Expression of quercetin equivalent μg per ml of sample (n=3)
30μg/mlVit.C
30μg/ml
DPPH 자유 라디칼 소거능은 하이드라질(hydrazyl)의 질소원자가 불안정한 상태로 쉽게 수소원자를 받아들이는 성질을 가지고 있어서 보라색에서 탈색되는 환원 정도를 기준으로 항산화능을 측정하는 방법을 사용하여 측정하였는데, 실시예 1화장료를 1.5배 희석한 액에서 약 76%의 소거능을 확인할 수 있었다. 이는 양성 대조군인 Vit.C(L-ascorbic acid)와 비교하여 다소 낮지만, 높은 DPPH 자유라디칼 소거능을 가지는 것임을 확인할 수 있었다.DPPH free radical scavenging ability was measured using a method of measuring antioxidant activity based on the degree of reduction that discolors from purple because the nitrogen atom of hydrazyl is unstable and has the property of easily accepting hydrogen atoms. Example 1 A removal ability of about 76% was confirmed in a solution diluted 1.5 times the cosmetic product. Although this is somewhat lower compared to the positive control Vit.C (L-ascorbic acid), it was confirmed that it has a high DPPH free radical scavenging ability.
30μg/mlVit.C
30μg/ml
상기 표 12의 ABTS 양이온 라디칼 소거능 측정 결과를 보면, 실시예 1화장료를 1.5배 희석한 액에서 약 99.9%의 소거능을 확인할 수 있으며, 이는 양성 대조군인 Vit.C(L-ascorbic acid)과 동등 내지 상대적으로 더 높은 ABTS 양이온라디칼 소거능을 가지는 것임을 확인할 수 있었다.Looking at the ABTS cation radical scavenging ability measurement results in Table 12 above, it can be seen that the scavenging ability of about 99.9% was confirmed in the 1.5-fold diluted liquid of Example 1 cosmetic, which is equivalent to or equal to Vit.C (L-ascorbic acid), a positive control. It was confirmed that ABTS had a relatively higher cation radical scavenging ability.
제조예 1 : 크림 제형의 화장품 제조Preparation Example 1: Preparation of cream-type cosmetics
상기 준비예 2에서 제조한 복합 한약재 발효물 10 중량% 및 상기 준비예 1-1에서 증류 추출물 90중량%를 균질기에서 혼합하여 화장료를 제조하였다.A cosmetic was prepared by mixing 10% by weight of the fermented complex herbal medicine prepared in Preparation Example 2 and 90% by weight of the distilled extract from Preparation Example 1-1 in a homogenizer.
상기 화장료를 이용하여 하기 표 13에 나타낸 성분 및 함량을 가지는 크림 제형의 피부용 화장품을 제조하였다.Using the above cosmetics, cream-type skin cosmetics having the ingredients and contents shown in Table 13 below were prepared.
제조예 2 : 스킨 제형의 화장품 제조Preparation Example 2: Preparation of skin formulation cosmetics
상기 준비예 2에서 제조한 복합 한약재 발효물 20 중량% 및 상기 준비예 1-1에서 증류 추출물 80 중량%를 균질기에서 혼합하여 화장료를 제조하였다.A cosmetic was prepared by mixing 20% by weight of the fermented complex herbal medicine prepared in Preparation Example 2 and 80% by weight of the distilled extract from Preparation Example 1-1 in a homogenizer.
상기 화장료를 이용하여 하기 표 14에 나타낸 성분 및 함량을 가지는 스킨 제형의 피부용 화장품을 제조하였다.Using the above cosmetics, cosmetics for skin in a skin formulation having the ingredients and contents shown in Table 14 below were prepared.
실험예 5 : 피부 안정성 실험 Experimental Example 5: Skin stability experiment
상기 제조예 1에서 제조한 크림 제형 화장품 및 제조예 2에서 제조한 스킨 제형 화장품을 intertek에 의뢰하여, 사람 피부에 대한 안정성(염증성 구진, 농포, 블랙헤드, 화이트헤드 발생 여부)을 평가하였다.The cream formulation cosmetics prepared in Preparation Example 1 and the skin formulation cosmetics prepared in Preparation Example 2 were commissioned by Intertek to evaluate their stability on human skin (whether inflammatory papules, pustules, blackheads, or whiteheads occurred).
평가 시험은 총 22명(평균나이 30세, 최소나이 24세, 최고나이 40세)이 참여하였으며, 4주간 화장품 사용 후 피부 트러블 유발 등 변화를 평가하였고 그 결과를 도 1a에 나타내었다. 그리고, 평가 대상 피시험자 5번, 14번, 20번의 최초 및 화장품 4주사용 후의 피부 안정성 평과 결과를 도 1a ~ 도 1d에 나타내었다. 도 1a ~ 도 1d에서 W0는 최초일을 의미하고, W4는 화장품 사용 4주 후를 의미한다.A total of 22 people (average age 30 years, minimum age 24 years, maximum age 40 years) participated in the evaluation test, and changes such as skin troubles were evaluated after using cosmetics for 4 weeks, and the results are shown in Figure 1a. In addition, the skin stability evaluation results for test subjects 5, 14, and 20 for the first time and after 4 weeks of use of cosmetics are shown in Figures 1A to 1D. In FIGS. 1A to 1D, W0 means the first day, and W4 means 4 weeks after using the cosmetics.
도 1a 및 도 2b를 통해 화이트헤드(좁쌀 여드름), 블랙헤드, 화농성 여드름, 농포(여드름)의 숫자가 현저히 줄어들었기에 (P<0.001) 이 제품은 논코메도제닉 시험에 유효성이 있음을 증명하며, 제조예 1, 2의 화장품 사용 4주 후, 4가지 병변의 합이 기준선과 비교하여 유의하게 증가하지 않아 제조예 1, 2의 화장품이 안전성 효과가 있다는 결과를 확인 받았다.1A and 2B, the number of whiteheads (millet acne), blackheads, purulent acne, and pustules (acne) was significantly reduced (P<0.001), proving that this product is effective in the non-comedogenic test. After 4 weeks of using the cosmetics of Preparation Examples 1 and 2, the sum of the four lesions did not significantly increase compared to the baseline, confirming the results that the cosmetics of Preparation Examples 1 and 2 had a safety effect.
실험예 6 : 화장품 내 잔류 살충물질 함유 여부 분석Experimental Example 6: Analysis of residual pesticides in cosmetics
상기 제조예 1에서 제조한 크림 제형 화장품 및 제조예 2에서 제조한 스킨 제형 화장품을 intertek에에 의뢰하여, 피부 및 인체 유해성분인 살충 물질(320종) 함유를 분석하였고, 그 결과를 도 2a ~ 도 2b(크림 제형) 및 도 3a ~ 도 3b(스킨 제형)에 나타내었다.The cream formulation cosmetics prepared in Preparation Example 1 and the skin formulation cosmetics prepared in Preparation Example 2 were commissioned by Intertek to analyze the content of insecticidal substances (320 types) that are harmful to the skin and human body, and the results are shown in Figures 2a to 2. 2b (cream formulation) and Figures 3a to 3b (skin formulation).
분석 결과, 제조예 1 및 제조예 2의 화장품 내 320종의 살충 물질을 포함하지 않는다는 결과를 받았다.As a result of the analysis, it was found that the cosmetics of Preparation Example 1 and Preparation Example 2 did not contain 320 types of insecticidal substances.
Claims (10)
상기 복합 한약재는 황칠나무(Dendropanax Morbifera), 비파나무 잎(Eriobotrya Japonica Leaf), 당잔대 잎 및 뿌리(Adenophora Stricta Leaf & Root), 새싹보리(Hordeum Vulgare), 삼백초(Saururus Chinensis), 개똥쑥 씨(Artemisia Annua seed) 및 티트리 잎(Tea Tree Leaf)을 포함하며,
상기 황칠나무는 황칠나무의 잎, 줄기 및 열매의 혼합물을 포함하는 것을 특징으로 하는 여드름 개선 화장료.Distilled extract of fermented complex herbal medicine; and complex herbal medicine fermentation products;
The complex herbal medicine includes Dendropanax Morbifera, Eriobotrya Japonica Leaf, Adenophora Stricta Leaf & Root, Hordeum Vulgare, Saururus Chinensis, and Artemisia seeds ( Contains Artemisia Annua seed and Tea Tree Leaf,
The Hwangchil tree is an acne improving cosmetic comprising a mixture of leaves, stems and fruits of the Hwangchil tree.
상기 저온 열수 추출물은 상기 복합 한약재 및 물을 1 : 3.0 ~ 6.0 중량비로 혼합한 후, 40 ~ 60℃하에서 16 ~ 24시간 동안 저온 열처리하여 수득한 것을 특징으로 하는 여드름 개선 화장료.The method of claim 1, wherein the fermented composite herbal medicine is a fermented product obtained by fermenting a low-temperature hot water extract of the composite herbal medicine,
The low-temperature hot water extract is an acne-improving cosmetic product obtained by mixing the complex herbal medicine and water at a weight ratio of 1:3.0 to 6.0 and then low-temperature heat treatment at 40 to 60° C. for 16 to 24 hours.
상기 복합 한약재를 사용하여, 복합 한약재 발효물의 증류 추출물 및 복합 한약재 발효물을 각각 제조하는 2단계;
상기 복합 한약재 발효물의 증류 추출물 및 복합 한약재 발효물을 혼합하여 혼합액을 제조하는 3단계;를 포함하는 공정을 수행하며,
1단계의 상기 황칠나무는 황칠나무의 잎, 줄기 및 열매의 혼합물을 포함하는 것을 특징으로 하는 여드름 개선 화장료의 제조방법.Step 1 of preparing a dried composite herbal medicine by ultrasonic washing a mixture of Hwangchil tree, loquat tree leaves, Tangjangi leaves and roots, barley sprouts, Trichytense aerobic herbacea, Artemisia seeds and tea tree leaves and then drying them;
Step 2 of producing a distilled extract and a fermented complex herbal medicine, respectively, using the complex herbal medicine;
Performing a process including 3 steps of mixing the distilled extract of the complex herbal medicine fermentation product and the complex herbal medicine fermentation product to prepare a mixed solution,
A method of producing an acne-improving cosmetic, characterized in that the Hwangchil tree in step 1 includes a mixture of leaves, stems, and fruits of the Hwangchil tree.
상기 복합 한약재를 80 ~ 90℃의 증기를 2 ~ 4시간 동안 가하여 찜처리하는 2-1단계;
찜 처리한 복합 한약재 및 물을 1 : 2.5 ~ 5.0 중량비로 혼합한 후, 85 ~ 95℃ 하에서 10 ~ 14시간 동안 열처리하는 2-2단계;
열처리물을 여과한 후 냉각 처리하여 열수 추출물을 수득하는 2-3단계;
열수 추출물에 막걸리 효모 및 영지버섯 균사체 또는 상황버섯 균사체를 포함하는 발효제를 혼합한 후, 25 ~ 40℃ 하에서 48 ~ 60시간 발효시킨 후, 여과하여 발효물을 수득하는 2-4단계; 및
상기 발효물을 진공 증류 추출공정을 수행하여 증류 추출물을 수득한 후, 여과하여 여과물을 수득하는 2-5단계;를 포함하는 공정을 수행하여 제조하는 것을 특징으로 하는 여드름 개선 화장료의 제조방법.The method of claim 7, wherein the distilled extract of the fermented complex herbal medicine is,
Step 2-1 of steaming the complex herbal medicine by applying steam at 80 to 90°C for 2 to 4 hours;
Step 2-2 of mixing steamed composite herbal medicine and water at a weight ratio of 1:2.5 to 5.0, followed by heat treatment at 85 to 95°C for 10 to 14 hours;
Steps 2-3 of filtering the heat-treated product and then cooling it to obtain a hot water extract;
Steps 2-4 of mixing the hot water extract with a fermentation agent containing makgeolli yeast and reishi mushroom mycelium or mycelium of Sanghwang mushroom, fermenting at 25 to 40°C for 48 to 60 hours, and then filtering to obtain a fermented product; and
A method for producing an acne-improving cosmetic, characterized in that it is manufactured by performing a process including steps 2-5 of performing a vacuum distillation extraction process on the fermented product to obtain a distilled extract, and then filtering the product to obtain a filtrate.
상기 복합 한약재 및 물을 1 : 3 ~ 5 중량비로 혼합한 후, 40 ~ 60℃ 하에서 16 ~ 24시간 동안 저온 열처리하는 2-1단계;
저온 열처리물을 여과한 후 냉각 처리하여 저온 열수 추출물을 수득하는 2-2단계;
저온 열수 추출물에 막걸리 효모 및 영지버섯 균사체 또는 상황버섯 균사체를 포함하는 발효제를 혼합한 후, 25 ~ 40℃ 하에서 45 ~ 60시간 발효시킨 후, 여과하여 발효물을 수득하는 2-3단계; 및
수득한 발효물을 열처리하여 발효물을 사멸시킨 후, 여과 처리한 여과물을 수득하는 2-4단계;를 포함하는 공정을 수행하여 제조하는 것을 특징으로 하는 여드름 개선 화장료의 제조방법.The method of claim 7, wherein the fermented complex herbal medicine is,
Step 2-1 of mixing the composite herbal medicine and water at a weight ratio of 1:3 to 5, followed by low-temperature heat treatment at 40 to 60°C for 16 to 24 hours;
Step 2-2 of filtering the low-temperature heat-treated product and then cooling it to obtain a low-temperature hot water extract;
Steps 2-3 of mixing low-temperature hot water extract with a fermentation agent containing makgeolli yeast and reishi mushroom mycelium or mycelium of Sanghwang mushroom, fermenting at 25 to 40°C for 45 to 60 hours, and then filtering to obtain a fermented product; and
A method for manufacturing an acne-improving cosmetic, characterized in that it is manufactured by performing a process including steps 2-4 of heat-treating the obtained fermented product to kill the fermented product and then obtaining a filtered filtrate.
열수 추출물 100 중량부에 대하여, 상기 발효제를 2.0 ~ 5.0 중량부로 혼합하는 것을 특징으로 하는 여드름 개선 화장료의 제조방법.The method of claim 8 or 9, wherein the makgeolli yeast includes yeast enzyme bacteria,
A method for producing an acne-improving cosmetic, characterized in that 2.0 to 5.0 parts by weight of the fermentation agent is mixed with 100 parts by weight of the hot water extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210157592A KR102637453B1 (en) | 2021-11-16 | 2021-11-16 | Cosmetic materials for improving acnegenic skin, Manufacturing method thereof and Cosmetics containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210157592A KR102637453B1 (en) | 2021-11-16 | 2021-11-16 | Cosmetic materials for improving acnegenic skin, Manufacturing method thereof and Cosmetics containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20230071414A KR20230071414A (en) | 2023-05-23 |
KR102637453B1 true KR102637453B1 (en) | 2024-02-15 |
Family
ID=86544530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210157592A KR102637453B1 (en) | 2021-11-16 | 2021-11-16 | Cosmetic materials for improving acnegenic skin, Manufacturing method thereof and Cosmetics containing the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102637453B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102143230B1 (en) | 2019-11-29 | 2020-08-11 | 대봉엘에스 주식회사 | Cosmetic composition comprising green barley sprout extract |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100870420B1 (en) | 2004-02-14 | 2008-11-26 | 이경록 | Hypoallergenic cosmetics formulation containing botanical extracts for acne skin |
KR101190943B1 (en) | 2004-10-12 | 2012-10-12 | 애경산업(주) | Cosmetic compositions for improving acne containing Oenothera odorata extract |
KR20110082292A (en) * | 2010-01-11 | 2011-07-19 | 유상훈 | Antipuritis and antiance effects of dendropanax morbifera lev. extract |
KR20150023601A (en) * | 2015-02-03 | 2015-03-05 | (주)아모레퍼시픽 | Composition Containing Extracts of Saururus chinensis |
KR20170065187A (en) * | 2015-12-03 | 2017-06-13 | 이경록 | Cosmetic composition for improving acne containing tea-tree leaves complex extract |
KR101817861B1 (en) * | 2016-06-15 | 2018-01-11 | 박숙우 | Herbal Shampoo Manufacturing Method using Enzyme Extract Fluid of Chinese Medicine and Dendropanax morbifera Lev |
KR20200065339A (en) * | 2018-11-30 | 2020-06-09 | 박숙우 | Manufacturing method using Dendropanax morbifera Lev and young barley leaves extraction fluid having whitening and anti-wrinkle activity |
-
2021
- 2021-11-16 KR KR1020210157592A patent/KR102637453B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102143230B1 (en) | 2019-11-29 | 2020-08-11 | 대봉엘에스 주식회사 | Cosmetic composition comprising green barley sprout extract |
Also Published As
Publication number | Publication date |
---|---|
KR20230071414A (en) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101146206B1 (en) | Cosmetic Composition And Composition of Skin External Application | |
KR20090055309A (en) | A cosmetic composition for skin whitening and treating wrinkles | |
CN114929195A (en) | Composition containing plant extract | |
KR101274778B1 (en) | Compositions for Improving Skin Conditions | |
KR101494661B1 (en) | Composition for hair or scalp treatment comprising fermented black garlic residue and method of preparing the same | |
KR20180031486A (en) | Functional composition for improving hair loss and hair growth comprising plant cell fermentation extract and functional cosmetic comprising the same | |
KR20130015339A (en) | Cream composition for treating acne | |
KR100564108B1 (en) | Cosmetic composition comprising plant extract having anti-aging effect | |
CN109106659A (en) | A kind of face cream and preparation method containing Chinese herbal medicine extract | |
KR101752232B1 (en) | Manufacturing Method of Composition for Hair growth promotion and Hair loss prevention | |
CN110946817A (en) | Natural herbal skin mucosa disinfectant special for private parts of women | |
KR20090017282A (en) | Cosmetic composition containing a medicinal liquor extracts of traditional oriental herb complex with the antioxidant effect | |
KR101397160B1 (en) | Cosmetic compositon for skin-irritation alleviation with Inula britannica var. chinensis, Cynanchi Radix and Lysimachia foenum-graecum Hance | |
Singh et al. | The portent plant with a purpose: Aloe vera | |
CN111973523A (en) | Anti-allergy purslane repairing mask and preparation method thereof | |
KR102637453B1 (en) | Cosmetic materials for improving acnegenic skin, Manufacturing method thereof and Cosmetics containing the same | |
KR20170137564A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR102303400B1 (en) | Preparation Methods of Fermentation Products Using JEJU Lava Seawater, JEJU Barley Yeast and Natural Plant and Cosmetic Compositions Having Thereof | |
KR102340001B1 (en) | Cosmetics material having inhibitor for NO activator and tyrosinase activator, Revitalizing cosmetics containing the same and Manufacturing method thereof | |
KR102451720B1 (en) | Cosmetic compositions comprising multi functional composition containing extract of scutellaria baicalensis, rosmarinus officinalis, houttuynia cordata, artemisia capillaris thunb and calendula officinalis having skin soothing, suppressing sebum, itching relieving or skin moisturizing effect and manufacturing methods thereof | |
KR20150109031A (en) | Cosmetic composition and a method of manufacturing | |
KR102324672B1 (en) | Composition comprising extract from liriope platyphylla and natural extract | |
KR20170136912A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR102637448B1 (en) | Cosmetic materials for improving atopy dermatitis, Manufacturing method thereof and Cosmetics containing the same | |
KR102561258B1 (en) | Composition for controlling sebum and improving pore comprising Jasminum Officinale, Salix Alba (willow) bark and Solanum melogena fruit extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |